<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Micronutrient supplementation in adults with HIV infection - Visser, ME - 2017 | Cochrane Library</title> <meta content="Micronutrient supplementation in adults with HIV infection - Visser, ME - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003650.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Micronutrient supplementation in adults with HIV infection - Visser, ME - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003650.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003650.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Micronutrient supplementation in adults with HIV infection" name="citation_title"/> <meta content="Marianne E Visser" name="citation_author"/> <meta content="marianne.visser@gmail.com" name="citation_author_email"/> <meta content="Solange Durao" name="citation_author"/> <meta content="South African Medical Research Council" name="citation_author_institution"/> <meta content="David Sinclair" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="James H Irlam" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Nandi Siegfried" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD003650.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003650.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003650.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003650.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Dietary Supplements; *HIV Infections [complications, mortality]; CD4 Lymphocyte Count; Cause of Death; HIV‐1; HIV‐2; Hospitalization [statistics &amp; numerical data]; Micronutrients [*administration &amp; dosage, deficiency]; Pregnancy Complications, Infectious [mortality]; Randomized Controlled Trials as Topic; Selenium [administration &amp; dosage]; Viral Load; Vitamin A [administration &amp; dosage]; Vitamin D [administration &amp; dosage]; Vitamins [administration &amp; dosage]; Zinc [administration &amp; dosage]; beta Carotene [administration &amp; dosage]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003650.pub4&amp;doi=10.1002/14651858.CD003650.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003650\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003650\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","ja","hr","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD003650.pub4",title:"Micronutrient supplementation in adults with HIV infection",firstPublishedDate:"May 18, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003650.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003650.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003650.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003650.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003650.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003650.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resultados&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003650.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003650.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003650.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003650.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6407 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003650.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-sec-0142"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-sec-0030"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-sec-0031"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-sec-0134"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/appendices#CD003650-sec-0147"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/table_n/CD003650StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/table_n/CD003650StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Micronutrient supplementation in adults with HIV infection</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#CD003650-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marianne E Visser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#CD003650-cr-0003">Solange Durao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#CD003650-cr-0004">David Sinclair</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#CD003650-cr-0005">James H Irlam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information#CD003650-cr-0006">Nandi Siegfried</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information/en#CD003650-sec-0161">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003650.pub4">https://doi.org/10.1002/14651858.CD003650.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003650-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003650-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003650-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003650-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003650-abs-0002">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003650-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003650-abs-0001" lang="en"> <section id="CD003650-sec-0001"> <h3 class="title" id="CD003650-sec-0001">Background</h3> <p>Micronutrient deficiencies are common among adults living with HIV disease, particularly in low‐income settings where the diet may be low in essential vitamins and minerals. Some micronutrients play critical roles in maintenance of the immune system, and routine supplementation could therefore be beneficial. This is an update of a Cochrane Review previously published in 2010. </p> </section> <section id="CD003650-sec-0002"> <h3 class="title" id="CD003650-sec-0002">Objectives</h3> <p>To assess whether micronutrient supplements are effective and safe in reducing mortality and HIV‐related morbidity of HIV‐positive adults (excluding pregnant women). </p> </section> <section id="CD003650-sec-0003"> <h3 class="title" id="CD003650-sec-0003">Search methods</h3> <p>We performed literature searches from January 2010 to 18 November 2016 for new randomized controlled trials (RCTs) of micronutrient supplements since the previous review included all trials identified from searches prior to 2010. We searched the CENTRAL (the Cochrane Library), Embase, and PubMed databases. Also we checked the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and the ClinicalTrials.gov trials registers. We also checked the reference lists of all new included trials. </p> </section> <section id="CD003650-sec-0004"> <h3 class="title" id="CD003650-sec-0004">Selection criteria</h3> <p>We included RCTs that compared supplements that contained either single, dual, or multiple micronutrients with placebo, no treatment, or other supplements. We excluded studies that were primarily designed to investigate the role of micronutrients for the treatment of HIV‐positive participants with metabolic morbidity related to highly active antiretroviral therapy (HAART). Primary outcomes included all‐cause mortality, morbidity, and disease progression. </p> </section> <section id="CD003650-sec-0005"> <h3 class="title" id="CD003650-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion, and appraised trial quality for risk of bias. Where possible, we presented results as risk ratios (RR) for dichotomous variables, as hazard ratios (HRs) for time‐to‐event data, and as mean differences (MD) for continuous variables, each with 95% confidence intervals (CIs). Since we were often unable to pool the outcome data, we tabulated it for each comparison. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD003650-sec-0006"> <h3 class="title" id="CD003650-sec-0006">Main results</h3> <p>We included 33 trials with 10,325 participants, of which 17 trials were new trials. Ten trials compared a daily multiple micronutrient supplement to placebo in doses up to 20 times the dietary reference intake, and one trial compared a daily standard dose with a high daily dose of multivitamins. Nineteen trials compared supplementation with single or dual micronutrients (such as vitamins A and D, zinc, and selenium) to placebo, and three trials compared different dosages or combinations of micronutrients. </p> <p><i>Multiple micronutrients</i> </p> <p>We conducted analyses across antiretroviral therapy (ART)‐naive adults (3 trials, 1448 participants), adults on antiretroviral therapy (ART) (1 trial, 400 participants), and ART‐naive adults with concurrent active tuberculosis (3 trials, 1429 participants). Routine multiple micronutrient supplementation may have little or no effect on mortality in adults living with HIV (RR 0.91, 95% CI 0.72 to 1.15; 7 trials, 2897 participants, <i>low certainty evidence</i>). </p> <p>Routine supplementation for up to two years may have little or no effect on the average of mean CD4+ cell count (MD 26.40 cells/mm³, 95% CI −22.91 to 75.70; 6 trials, 1581 participants, <i>low certainty evidence</i>), or the average of mean viral load (MD −0.1 log<sub>10</sub>viral copies, 95% CI −0.26 to 0.06; 4 trials, 840 participants, <i>moderate certainty evidence</i>). One additional trial in ART‐naïve adults did report an increase in the time to reach a CD4+ cell count &lt; 250 cells/mm³ after two years of high dose supplementation in Botswana (HR 0.48, 95% CI 0.26 to 0.88; 1 trial, 439 participants). However, the trial authors reported this effect only in the trial arm that received multiple micronutrients plus selenium (not either supplementation alone), which is inconsistent with the findings of other trials that used similar combinations of micronutrients and selenium. </p> <p>In one additional trial that compared high‐dose multiple micronutrient supplementation with standard doses in people on ART, peripheral neuropathy was lower with high dose supplements compared to standard dose (incidence rate ratio (IRR) 0.81, 95% CI 0.7 to 0.94; 1 trial, 3418 participants), but the trial was stopped early due to increased adverse events (elevated alanine transaminase (ALT) levels) in the high dose group. </p> <p><i>Single or dual micronutrients</i> </p> <p>None of the trials of single or dual micronutrient supplements were adequately powered to assess for effects on mortality or morbidity outcomes. No clinically significant changes in CD4 cell count (data not pooled, 14 trials, 2370 participants, <i>very low or low certainty evidence</i> ) or viral load (data not pooled, seven studies, 1334 participants, <i>very low or low certainty evidence</i> ), were reported. Supplementation probably does increase blood concentrations of vitamin D and zinc (data not pooled, vitamin D: 4 trials, 299 participants, zinc: 4 trials, 484 participants, <i>moderate certainty evidence</i> ) and may also increase blood concentrations of vitamin A (data not pooled, 3 trials, 495 participants, <i>low certainty evidence</i>), especially in those who are deficient. </p> </section> <section id="CD003650-sec-0007"> <h3 class="title" id="CD003650-sec-0007">Authors' conclusions</h3> <p>The analyses of the available trials have not revealed consistent clinically important benefits with routine multiple micronutrient supplementation in people living with HIV. Larger trials might reveal small but important effects. </p> <p>These findings should not be interpreted as a reason to deny micronutrient supplements for people living with HIV where specific deficiencies are found or where the person's diet is insufficient to meet the recommended daily allowance of vitamins and minerals. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003650-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003650-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003650-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003650-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003650-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003650-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003650-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003650-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003650-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003650-abs-0004" lang="en"> <h3>Micronutrient supplements for non‐pregnant adults with HIV infection</h3> <p>Cochrane researchers conducted a review of the effects of micronutrient supplements for people living with HIV. This is an update of a Cochrane Review previously published in 2010. After searching for relevant trials up to 18 November 2016, the review authors included 33 trials. Thirteen of these trials included people not on HIV treatment and were conducted in Thailand, Peru, and eight African countries. Nineteen trials included people on HIV treatment and were conducted in North America, Europe, Brazil, Singapore, Thailand, Botswana, and Uganda. One trial from China did not state whether people living with HIV were on treatment or not. Some trials looked at the effects of taking supplements with multiple micronutrients whereas others looked at supplementation with single vitamins or minerals. </p> <p><b>What are micronutrient supplements and how might they help people living with HIV?</b> </p> <p>Micronutrient supplements contain vitamins or minerals, or both, that are essential to good health. Many of these vitamins play important roles in maintaining the human immune system, which helps to fight off infections. </p> <p>Infection with HIV causes a progressive destruction of the immune system, which leaves people vulnerable to frequent infections. Many people living with HIV, especially in low‐income countries, are also undernourished and many consume diets deficient that these essential micronutrients. Supplementation could therefore help people living with HIV to stay healthy for longer by strengthening their immune system or assisting recovery from infections. </p> <p><b>What the research says</b> </p> <p><i>Multiple micronutrients</i> </p> <p>Providing a daily supplement that contains multiple vitamins and minerals may have little or no effect on reducing deaths in people living with HIV, whether they are taking antiretroviral drugs or not (<i>low certainty evidence</i> ). Daily supplements may have little or no effect on HIV disease progression as measured by CD4 cell count (<i>low certainty evidence</i> ) or HIV viral load (<i>low or moderate certainty evidence</i>). </p> <p><i>Single or dual micronutrients</i> </p> <p>We do not know whether supplements that contain single vitamins or minerals reduce deaths (<i>very low certainty evidence</i> ) or slow disease progression (<i>very low/low certainty evidence</i> ) in people living with HIV. Supplementation with vitamin A, D, zinc, or selenium may improve the level of each vitamin in a person's blood, especially those with low levels before supplementation (<i>low/moderate certainty evidence</i>). </p> <p>These findings do not mean that an adequate dietary intake for people living with HIV is not important. It is also not a reason to deny micronutrient supplements for those in whom a deficiency has been clinically demonstrated, or who are unlikely to meet the recommended daily allowance of vitamins and minerals. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003650-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003650-sec-0142"></div> <h3 class="title" id="CD003650-sec-0143">Implications for practice</h3> <section id="CD003650-sec-0143"> <p>To date trials of routine multiple micronutrient supplementation have not demonstrated consistent clinically important benefits on HIV disease progression or mortality. However, the trials are generally too small to confidently exclude the possibility of important effects. </p> <p>These findings should not be interpreted as a reason to deny supplementation where specific deficiencies have been demonstrated (such as vitamin D, zinc, and selenium), or where the person's diet is unlikely to meet the recommended daily allowance of vitamins and minerals. </p> </section> <h3 class="title" id="CD003650-sec-0144">Implications for research</h3> <section id="CD003650-sec-0144"> <p>Furthermore, adequately powered studies with sufficient follow‐up periods are still required to confidently prove or exclude any long‐term clinical benefit of routine supplementation. </p> <p>Such research should not be to the detriment of ART, as this remains the one intervention to date that has consistently been shown to reduce morbidity and mortality, and improve the nutritional status of adults living with HIV/AIDS. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003650-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003650-sec-0030"></div> <div class="table" id="CD003650-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection (with and without concurrent tuberculosis, with and without ART)<br/> <b>Settings:</b> all settings<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard or high dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 8 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (72 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.72 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2897<br/> (7 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on mortality</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>Follow‐up: 11 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> <p>(85 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> </p> <p>(0.61 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>881</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on hospital admissions</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 6 weeks to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>147 to 483 cells/mm</b>³ </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient group was</p> <p><b>26.40 cells/mm</b> ³ <b>higher</b> </p> <p>(22.91 lower to 75.70 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1581<br/> (6 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3,6</sup> </p> <p>due to indirectness and inconsistency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> <p>Follow‐up: 6 weeks to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>4.1 to 5.4 log<sub>10</sub>copies/mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.10 log<sub>10</sub>copies/mL lower</b> </p> <p>(0.26 lower to 0.06 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>840</p> <p>(4 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients probably have little or no effect on viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nutritional status</b> </p> <p>Follow‐up: 4 weeks to 1.9 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1007<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,8,9</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on nutritional status parameters</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; BMI: body mass index; CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: most trials were at low risk of selection bias and used placebos to prevent performance or detection bias.<br/> <sup>2</sup>No serious heterogeneity: none of the trials found statistically significant effects overall (although one small subgroup from one trial in Tanzania did find a statistically significant difference this is probably a chance finding).<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: although most trials reported this outcome, only one of these (from Uganda using standard dose micronutrients) included a substantial number of adults on ART in line with current recommendations. The other trials used standard or high dose micronutrients and were conducted in ART‐naive adults (in Botswana, Zambia, and Thailand), and adults with concurrent tuberculosis (in Tanzania and Malawi).<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important effects and no effect. The overall meta‐analysis remains underpowered to confidently exclude effects.<br/> <sup>5</sup>Downgraded by 2 for very serious indirectness: these two trials were conducted in Thailand (high dose micronutrients in ART‐naive adults) and Uganda (standard dose micronutrients in adults on ART). The finding of no effect may not apply to all populations and settings.<br/> <sup>6</sup>Downgraded by 1 for serious inconsistency: in total eight trials reported a measure of CD4+ cell count although we could only include six trials in this meta‐analysis. Of note, one recent trial in Botswana among ART‐naive adults (not included in the meta‐analysis) reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation. This finding is inconsistent with other trials that used similar combinations of micronutrients and selenium.<br/> <sup>7</sup>Downgraded by 1 for serious indirectness: in total four trials in ART‐naive adults, with concurrent TB (in Tanzania and Malawi) or without TB (in Kenia and Thailand), reported viral load. The finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>8</sup>Downgraded by 2 for serious indirectness: only three trials (from Uganda, Zambia, and Tanzania) reported measures of nutritional status (BMI, weight, mid‐upper arm circumference (MUAC), lean body mass). The finding of no effect may not apply to all populations and settings.<br/> <sup>9</sup>Downgraded by 1 for serious imprecision: we were unable to pool data but the 95% CIs of the individual trials were wide and included clinically important effects and no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003650-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin A compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin A compared to placebo for adults with HIV infection currently taking ART or not</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> any<br/> <b>Intervention:</b> vitamin A (single dose or daily dose)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count (cells/mm</b> ³<b>)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A may have little or no short‐term effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load (log<sub>10</sub>copies/mL)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>495<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A may have little or no short‐term effect on viral load</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in vitamin A concentrations (µmol/L)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>495</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,4,5</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A may increase blood concentrations of persons with HIV with low baseline concentrations </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for serious risk of bias: one trial in Kenya with 400 participants reported high attrition overall (11.5%) and the trial authors stated that participants who were lost to follow‐up had more advanced HIV disease and were more likely to be vitamin A deficient (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>).<br/> <sup>2</sup>No serious heterogeneity: none of the trials found statistically significant effects.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: trials were conducted in the USA and Kenya, and most participants were not on antiretroviral therapy (ART). This may not completely exclude the possibility of effects in some settings or populations.<br/> <sup>4</sup>No serious imprecision: no statistically significant differences were seen. Although two trials were underpowered, one trial in Kenya with 400 participants was adequately powered to reliably detect a clinically beneficial effect on CD4 cell count, viral load, and blood vitamin A concentrations (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>).<br/> <sup>5</sup>No serious heterogeneity: a statistical significant increase in blood vitamin concentrations was reported in one trial from Kenya with 400 participants. Baseline blood vitamin concentrations of these participants were much lower than the 95 participants in the other two trials in the USA. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003650-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vitamin D compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin D compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> any<br/> <b>Intervention:</b> vitamin D (repeated single doses or daily dose with or without additional calcium)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin D</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> </p> <p>(165 to 513)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> </p> <p>(0.65 to 2.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if vitamin D supplements have any effect on mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count (cells/mm</b> ³<b>)</b> <br/> Follow‐up: 16 weeks to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> <p>due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D supplements may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load (log<sub>10</sub>copies/mL)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo group was</p> <p><b>3.78</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.66 lower</b> </p> <p>(1.37 lower to 0.05 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 participants</p> <p>(1 trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5,6</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if vitamin D supplements have an effect on viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in 25(OH) vitamin D concentrations (ng/mL)</b> <br/> Follow‐up: 16 weeks to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7,8</sup> </p> <p>due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D supplements probably increase blood 25(OH) vitamin D levels</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: the included trials were generally at low risk of bias.<br/> <sup>2</sup>Downgraded by 2 for serious indirectness: only a single trial from Guinea‐Bissau reports the number of deaths after 12 months follow‐up in HIV‐positive participants on treatment for active tuberculosis (<a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>).<br/> <sup>3</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both a relative risk reduction and relative risk increase of greater than 25%.<br/> <sup>4</sup>Downgraded by 2 for serious indirectness: no changes in mean or median CD4 cell counts were reported from these four small trials from Italy (<a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>), the USA (<a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>), Guinea‐Bissau (<a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>), or Denmark (<a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>). This doesn't exclude the possibility of effects in some populations.<br/> <sup>5</sup>Downgraded by 2 for very serious indirectness: this is a single very small trial from the USA.<br/> <sup>6</sup>Downgraded by 1 for serious imprecision: the trial is very small, and the 95% CI is wide and includes no effect.<br/> <sup>7</sup>No serious heterogeneity: all four studies report a statistical significant increase in blood 25(OH) vitamin D concentrations (ng/mL).<br/> <sup>8</sup>Downgrade by 1 for serious risk of indirectness: all studies were conducted in high income countries (Italy, Canada, Denmark, and the USA). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003650-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Zinc compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> any<br/> <b>Intervention:</b> zinc (daily or weekly dose)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Zinc</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 6 to 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> <p>(58 to 315)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> <br/> (0.53 to 2.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if zinc supplements have any effect on mortality</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of diarrhoea</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.18 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if zinc supplements have any effect on the frequency of diarrhoea</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in CD4 cell count (cells/mm</b> ³<b>)</b> </p> <p>Follow‐up: 1 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>431<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,6</sup> </p> <p>due to indirectness and inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc supplements may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in viral load (log<sub>10</sub>copies/mL)</b> </p> <p>Follow‐up: 1 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,7</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc supplements may have little or no effect on viral load</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in blood zinc concentrations</b> </p> <p>Follow‐up: 1 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc supplements probably increase blood zinc concentrations of persons with HIV with low baseline concentrations </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; RR: risk ratio; OR: odds ratio; HR: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: the included studies were generally at low risk of bias.<br/> <sup>2</sup>Downgraded by 1 for serious indirectness: the available data is from limited settings and populations. The findings are not easily generalized to other populations.<br/> <sup>3</sup>Downgraded by 2 for serious imprecision: the 95% CI around the absolute effect is very wide and crosses 1. The overall meta‐analysis is underpowered to confidently exclude effects.<br/> <sup>4</sup>Downgraded by 2 for very serious indirectness: this finding is from a single study in the USA and may not be applicable to other settings.<br/> <sup>5</sup>Downgraded by 1 for serious imprecision: although the 95% CI does not cross the line of no effect this trial is underpowered to detect or exclude clinically important differences.<br/> <sup>6</sup>Downgrade by 1 for serious inconsistency: one very small trial from Singapore reports a marginal improvement in median CD4 count after 6 months of standard dose supplements (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>), and one study reports a significant reduction in the risk of decline of CD4+ to &lt; 200 in those taking standard supplements (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>). Two other small studies using high dose supplements report no statistically significant difference (<a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>).<br/> <sup>7</sup>Downgraded by 1 for serious imprecision: all three trials were underpowered to include or exclude clinically important effects (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>).<br/> <sup>8</sup>No serious inconsistency: three trials report an increase in blood zinc concentrations over time. The participants in one trial that did not report an increase in blood concentrations after supplementation, were not deficient in zinc at baseline (<a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003650-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Selenium compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Selenium compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> all settings<br/> <b>Intervention:</b> selenium (daily dose)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Selenium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> <br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> <br/> (65 to 232) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.4</b> <br/> (0.21 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to risk of bias, indirectness, and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if selenium supplements reduce hospital admissions</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in CD4 cell count (cells/mm</b> ³<b>)</b> </p> <p>Follow‐up: 9 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1187 participants<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium supplements may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in viral load (log<sub>10</sub>copies/mL)</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439 participants<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium supplements may have little or no effect on viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in selenium concentrations (µg/L)</b> <br/> Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium supplements may increase blood selenium concentrations</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; CI: confidence interval; RR: risk ratio; HR: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for serious risk of bias: high attrition due to participants with incomplete medical records. In addition, fewer participants in the placebo group compared to the selenium group were on antiretroviral therapy (ART) at baseline (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>).<br/> <sup>2</sup>Downgraded by 1 for serious indirectness: only a single trial is available from the USA in HIV‐positive intravenous drugs users. This is not easily generalized to other HIV‐positive populations.<br/> <sup>3</sup>Downgraded by 1 for serious imprecision: this trial is underpowered to detect clinically important differences.<br/> <sup>4</sup>Downgraded by 1 for serious risk of bias: two of the three trials reported high attrition rates (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). In one trial fewer participants in the placebo group compared to the selenium group were on ART at baseline (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>).<br/> <sup>5</sup>Downgraded by 1 for serious imprecision: three of the four trials were underpowered to include or exclude clinically important effects (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>; <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>). One trial from Botswana was adequately powered and reported no effect on the decline in CD4 cell counts of ART‐naive participants (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>).<br/> <sup>6</sup>No serious risk of bias: the included trial was at low risk of selection and performance bias (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>). The trial authors performed multiple imputation of viral load data. The trial authors did not provide details.<br/> <sup>7</sup>Downgraded by 2 for serious indirectness: only a single trial is available from Botswana in participants not on ART (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>).<br/> <sup>8</sup>No serious heterogeneity: all three trials reported either an increase in the mean blood selenium concentration of participants or the proportion of participants with selenium concentrations above a certain threshold level.<br/> <sup>9</sup>Downgraded by 1 for indirectness: participants in two of the three included trials were not deficient in selenium at baseline (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). The third trial reported data on participants who were selenium deficient at baseline; however it was a small subsample of the main trial from Botswana (Sales 2010). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003650-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003650-sec-0031"></div> <section id="CD003650-sec-0032"> <h3 class="title" id="CD003650-sec-0032">Description of the condition</h3> <p>Despite a substantial decrease in the number of new HIV infections during the past decade, recent estimates from the United Nations Joint Programme on HIV/AIDS (UNAIDS) indicate that 35 million people were still living with HIV worldwide in 2013 (<a href="./references#CD003650-bbs2-0120" title="Joint United Nations Programme on HIV/AIDS. Fact sheet 2014. www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2014/20140716_FactSheet_en.pdf (accessed 21 April 2015). ">UNAIDS 2014</a>). The HIV/AIDS pandemic has severely affected sub‐Saharan Africa, more than any other part of the world. With about a tenth of the world's population, the region is home to more than two‐thirds of all people living with HIV worldwide, an estimated 24.7 million adults and children (<a href="./references#CD003650-bbs2-0120" title="Joint United Nations Programme on HIV/AIDS. Fact sheet 2014. www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2014/20140716_FactSheet_en.pdf (accessed 21 April 2015). ">UNAIDS 2014</a>). Globally, more than one‐third of HIV‐positive adults receive antiretroviral therapy (ART) (<a href="./references#CD003650-bbs2-0120" title="Joint United Nations Programme on HIV/AIDS. Fact sheet 2014. www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2014/20140716_FactSheet_en.pdf (accessed 21 April 2015). ">UNAIDS 2014</a>). Earlier initiation of ART, in line with recent recommendations, is a challenge to implement in many countries, especially those in resource‐limited settings (<a href="./references#CD003650-bbs2-0123" title="World Health Organization. Guideline on when to start antiretroviral therapy and on pre‐exposure prophylaxis for HIV. September 2015. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf (accessed 08 March 2016). ">WHO 2015</a>). </p> <p>Adults living with HIV may also have micronutrient deficiencies, particularly those from communities at high risk of food insecurity since diets are frequently inadequate to meet the recommended daily requirements (<a href="./references#CD003650-bbs2-0098" title="GebrehiwotT , van derVeenA . Coping with food insecurity on a micro‐scale: evidence from Ethiopian rural households. Ecology of Food and Nutrition2014;53(2):214‐40. ">Gebrehiwot 2014</a>). A recent review reported that people living with HIV who experience food insecurity tended to have lower CD4 counts than their counterparts (<a href="./references#CD003650-bbs2-0089" title="AibibulaW , CoxJ , HamelinA , MamiyaH , KleinMB , BrassardP . Food insecurity and low CD4 count among HIV‐infected people: a systematic review and meta‐analysis. AIDS Care2016;28(12):1577‐85. ">Aibibula 2016</a>). Deficiencies of micronutrients are more pronounced in individuals with advanced disease, as a consequence of reduced nutrient intake due to AIDS and opportunistic infections, and excessive losses due to diarrhoea, malabsorption, and parasitic infections. Furthermore, in sub‐Saharan Africa, a region severely affected by the HIV/AIDS pandemic, protein energy malnutrition (PEM) is common. PEM refers to inadequate protein and energy intake and is usually associated with multiple micronutrient insufficiency (<a href="./references#CD003650-bbs2-0103" title="IrlamJ , HusseyG , DhansayM . The effects of nutritional interventions in HIV/AIDS: Micronutrients. In: ASSAf Study Panel, editor(s). HIV/AIDS, TB and Nutrition: Scientific inquiry into the nutritional influences on human immunity with special reference to HIV infection and active TB in South Africa. Pretoria: Academy of Science of South Africa (ASSAf), 2007:143‐51. ">Irlam 2007</a>). </p> </section> <section id="CD003650-sec-0033"> <h3 class="title" id="CD003650-sec-0033">Description of the intervention</h3> <p>Micronutrient supplements are either single or multiple formulations of vitamins and trace elements. </p> </section> <section id="CD003650-sec-0034"> <h3 class="title" id="CD003650-sec-0034">How the intervention might work</h3> <p>Micronutrients play a critical role in the maintenance of a functional immune system. The interactions between micronutrients and the components of the immune response are multifaceted and complex <a href="./references#CD003650-bbs2-0094" title="ChandraRK . Nutrition and the immune system: an introduction. Journal of Nutrition1997;66(2):460S‐3S. ">Chandra 1997</a>; <a href="./references#CD003650-bbs2-0110" title="RaitenDJ , Sakr AshourFA , RossAC , MeydaniSN , DawsonHD , StephensenCB , et al. Inflammation and Nutritional science for Programs/Policies and interpretation of research Evidence (INSPIRE). Journal of Nutrition2015;145(5):1039S‐108S. ">Raiten 2015</a>). Several observational studies have suggested that micronutrient deficiencies may hasten clinical disease progression in HIV‐positive adults. Low blood levels of vitamin A, B12, zinc, and selenium have been related to increased HIV progression (<a href="./references#CD003650-bbs2-0100" title="GrahamNM , SorensenD , OdakaN , BrookmeyerR , ChanD , WillettWC , et al. Relationship of serum copper and zinc levels to HIV‐1 seropositivity and progression to AIDS. Journal of Acquired Immune Deficiency Syndromes1991;4(10):976‐80. [PUBMED: 1890606] ">Graham 1991</a>; <a href="./references#CD003650-bbs2-0106" title="KupkaR , MsamangaGI , SpiegelmanD , MorrisS , MugusiF , HunterDJ , et al. Selenium status is associated with accelerated HIV disease progression among HIV‐infected pregnant women in Tanzania. Journal of Nutrition2004;134(10):2556‐60. ">Kupka 2004</a>; <a href="./references#CD003650-bbs2-0118" title="TangAM , GrahamNMH , ChandraRK , SaahAJ . Low serum vit B12 concentrations are associated with faster Human immunodeficiency virus type 1 (HIV‐1) disease progression. Journal of Nutritiom1997;127(2):345‐51. ">Tang 1997</a>) or death in this population (<a href="./references#CD003650-bbs2-0091" title="BaumMK , Shor‐PosnerG , LaiS , ZhangG , LaiH , FletcherMA , et al. High risk of HIV‐related mortality is associated with selenium deficiency. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;15(5):370‐4. ">Baum 1997</a>; <a href="./references#CD003650-bbs2-0092" title="BaumMK , CampaA , LaiS , LaiH , PageJB . Zinc status in human immunodeficiency virus type 1 infection and illicit drug use. Clinical Infectious Diseases2003;37 Suppl 2:S117‐23. [PUBMED: 12942385] ">Baum 2003</a>; <a href="./references#CD003650-bbs2-0114" title="SembaRD , GrahamNM , CaiaffaWT , MargolickJB , ClementL , VlahovD . Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Archives of Internal Medicine1993;153(18):2149‐54. ">Semba 1993</a>). Most participants in these earlier studies were not receiving ART at the time. More recently, vitamin D deficiency, which is assessed by low 25‐hydroxy vitamin D levels, has been associated with increased disease progression of untreated (<a href="./references#CD003650-bbs2-0069" title="MehtaS , FawziWW . Micronutrient supplementation as adjunct treatment for HIV‐infected patients. Clinical Infectious Diseases2010;50(12):1661‐3. ">Mehta 2010</a>) or treated HIV disease (<a href="./references#CD003650-bbs2-0117" title="SudfeldCR , WangM , AboudS , GiovanucciEL , MugusiFM , FawziWW . Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy. PLoS ONE2012;7(6):e40036. ">Sudfeld 2012</a>; <a href="./references#CD003650-bbs2-0121" title="ViardJP , SouberbielleJC , KirkO , ReekieJ , KnyszB , LossoM , et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS2011;25(10):1305‐15. ">Viard 2011</a>), and impaired CD4 cell count recovery of HIV‐positive men and women on antiretroviral therapy (ART) (<a href="./references#CD003650-bbs2-0090" title="AzizM , LivakB , Burke‐MillerJ , FrenchA , GlesbyMJ , SharmaA , et al. Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study (WIHS) participants with advanced disease on HAART. AIDS2013;27(4):573‐8. ">Aziz 2013</a>; <a href="./references#CD003650-bbs2-0112" title="RossAC , JuddS , KumariM , HilemanC , StorerN , LabbatoD , et al. Vitamin D is linked to carotid intima‐media thickness and immune reconstitution in HIV‐positive individuals. Antiviral Therapy2011;16(4):555‐63. ">Ross 2011</a>). </p> <p>Widespread micronutrient supplementation may lessen the effects of concurrent micronutrient deficiency and help to reduce the morbidity and mortality due to HIV (<a href="./references#CD003650-bbs2-0115" title="SembaRD , TangAM . Micronutrients and the pathogenesis of human immunodeficiency virus infection. British Journal of Nutrition1999;81(3):181‐9. ">Semba 1999</a>). It has also been suggested that micronutrient supplementation may enhance the CD4 cell responses of individuals on ART who demonstrate adequate viral suppression (<a href="./references#CD003650-bbs2-0119" title="TangAM , LanzelottiJ , HendricksK , GerriorJ , GhoshM , WoodsM , et al. Micronutrients: current issues for HIV care providers. AIDS2005;19(9):847‐61. ">Tang 2005</a>). </p> <p>Assessing the effectiveness of micronutrient supplementation in participants with inflammation requires special consideration. Acute inflammation results in the redistribution of micronutrients due to changes in plasma proteins and may therefore impact on the validity of nutrient biomarkers, such as serum micronutrient concentrations (<a href="./references#CD003650-bbs2-0110" title="RaitenDJ , Sakr AshourFA , RossAC , MeydaniSN , DawsonHD , StephensenCB , et al. Inflammation and Nutritional science for Programs/Policies and interpretation of research Evidence (INSPIRE). Journal of Nutrition2015;145(5):1039S‐108S. ">Raiten 2015</a>). </p> </section> <section id="CD003650-sec-0035"> <h3 class="title" id="CD003650-sec-0035">Why it is important to do this review</h3> <p>A previous version of this Cochrane review included 30 trials: 20 trials of single micronutrient supplements (vitamin A, vitamin D, zinc, and selenium) and 10 of multiple micronutrient supplements. Eight trials were undertaken in child populations and four trials were conducted among pregnant and lactating women (<a href="./references#CD003650-bbs2-0126" title="IrlamJ , VisserMME , RollinsNN , SiegfriedN . Micronutrient supplementation in children and adults with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD003650.pub3] ">Irlam 2010</a>). The review found no conclusive evidence that micronutrient supplementation effectively reduces or increases morbidity or mortality in HIV‐positive adults. </p> <p>The HIV/AIDS pandemic has had a major impact on global health, nutrition, and overall socioeconomic development. An update of the review based on recent, valid research is therefore important. Micronutrient supplements have potential benefit for people living with HIV infection. However, in order to understand the magnitude of this benefit and how supplements should be positioned alongside the proven advantages of antiretroviral drugs, a robust evidence‐base to guide policy and practice is required. </p> <p>At the request of the World Health Organization (WHO), two separate Cochrane Reviews on the role of micronutrient supplementation were published for HIV‐positive pregnant women (<a href="./references#CD003650-bbs2-0116" title="SiegfriedN , IrlamJH , VisserME , RollinsNN . Micronutrient supplementation in pregnant women with HIV infection. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD009755] ">Siegfried 2012</a>) and children (<a href="./references#CD003650-bbs2-0104" title="IrlamJH , SiegfriedN , VisserME , RollinsNC . Micronutrient supplementation for children with HIV infection. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010666] ">Irlam 2013</a>). The primary focus of this Cochrane review is therefore on the role of micronutrient supplementation in HIV‐positive non‐pregnant adults. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003650-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003650-sec-0036"></div> <p>To assess whether micronutrient supplements are effective and safe in reducing mortality and HIV‐related morbidity in HIV‐positive adults (excluding pregnant women). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003650-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003650-sec-0037"></div> <section id="CD003650-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003650-sec-0039"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) of micronutrient supplements compared with placebo, no treatment, or other supplements (including variations in quantity or formulation). </p> </section> <section id="CD003650-sec-0040"> <h4 class="title">Types of participants</h4> <p>HIV‐positive adults, defined as people ≥ 15 years of age who were HIV‐positive (<a href="./references#CD003650-bbs2-0122" title="World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV‐related diseases in adults and children. Geneva: World Health Organization, 2007. ">WHO 2007</a>). Two other Cochrane reviews have addressed micronutrient supplementation for HIV‐positive children and pregnant women (<a href="./references#CD003650-bbs2-0104" title="IrlamJH , SiegfriedN , VisserME , RollinsNC . Micronutrient supplementation for children with HIV infection. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010666] ">Irlam 2013</a>; <a href="./references#CD003650-bbs2-0116" title="SiegfriedN , IrlamJH , VisserME , RollinsNN . Micronutrient supplementation in pregnant women with HIV infection. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD009755] ">Siegfried 2012</a>). We included trials that recruited both HIV‐positive adults and children if 80% or more of the participants were HIV‐positive adults. </p> <p>We included trials that recruited antiretroviral therapy (ART)‐naive participants, as well as those that recruited participants on ART. Since the objective of this Cochrane Review is on the adjunctive role of micronutrients on mortality and HIV‐related morbidity, we excluded studies that were primarily designed to investigate the role of micronutrients for the treatment of HIV‐positive participants with metabolic morbidity related to ART. A Cochrane review on treatment for dyslipidaemia in HIV infection is in progress (<a href="./references#CD003650-bbs2-0107" title="Martí‐CarvajalAJ , CrucianiM . Pharmacological interventions for treating dyslipidemia in patients with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD008869] ">Martí‐Carvajal 2010</a>). </p> <p>We included trials conducted in populations with and without HIV infection if outcome data were available for HIV‐positive participants. </p> <p>We included trials that involved participants with tuberculosis with and without HIV infection if outcome data were available for participants with HIV, regardless of whether the trial authors stratified the randomization of trial participants according to HIV infection status. We excluded studies that did not report outcome data for HIV‐positive participants. </p> </section> <section id="CD003650-sec-0041"> <h4 class="title">Types of interventions</h4> <p>We included trials of micronutrient supplementation that included vitamins (A, D, E, C, B1, B2, niacin, B6, B12, K, folate, beta‐carotene), trace elements (zinc, selenium, magnesium, iron, iodine, copper, manganese, chromium, cobalt, molybdenum), or combinations of the above only. We described a supplement as a standard dose supplement if the trial provided a single micronutrient, or a combination of micronutrients, at the level of the Recommended Daily Intake (RDA). We described any supplement containing a single micronutrient, or a combination of micronutrients in multiples of the RDA, as a high‐dose supplement. We excluded studies that assessed the effect of adding micronutrients to foods (food fortification). </p> </section> <section id="CD003650-sec-0042"> <h4 class="title">Types of outcome measures</h4> <section id="CD003650-sec-0043"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003650-list-0001"> <li> <p>All‐cause mortality</p> </li> <li> <p>Morbidity (frequency, types, and duration of episodes of opportunistic infections; incidence of AIDS as defined by each trial; hospital admissions; and other types of illnesses related to HIV infection as reported in each study) </p> </li> <li> <p>Disease progression according to either the World Health Organization (<a href="./references#CD003650-bbs2-0122" title="World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV‐related diseases in adults and children. Geneva: World Health Organization, 2007. ">WHO 2007</a>), or the Centers for Disease Control and Prevention (CDC) clinical staging system (<a href="./references#CD003650-bbs2-0113" title="SchneiderE , WhitmoreS , GlynnKM , DominguezK , MitschA , McKennaMT . Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged &lt;18 months and for HIV infection and AIDS among children aged 18 months to &lt;13 years‐‐UnitedStates, 2008. Morbidity and Mortality Weekly Report. Recommendations and reports2008;57(RR‐10):1‐12. ">Schneider 2008</a>), as reported in each included trial </p> </li> </ul> </p> </section> <section id="CD003650-sec-0044"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003650-list-0002"> <li> <p>Virological response: proportion of participants who maintained an undetectable viral load and change in HIV‐RNA levels (mean relative change (percent) or mean absolute change, compared with baseline, and standard deviation (SD)) </p> </li> <li> <p>Virological failure: proportion of participants who discontinued or switched ART due to virological failure, as defined by each included trial </p> </li> <li> <p>Markers of immune response, such as change in absolute CD4+ T lymphocyte count (mean relative change (percent) or mean absolute change, compared with baseline, and SD) </p> </li> <li> <p>Nutritional status, including measurements such as bodyweight, Body Mass Index (BMI), and body composition </p> </li> <li> <p>Biochemical markers, such as serum micronutrient concentrations</p> </li> </ul> </p> <p>We excluded studies that only reported data that related to biochemical markers from this review. </p> <section id="CD003650-sec-0045"> <h6 class="title">Adverse events</h6> <p>We extracted data on all adverse events that we judged to be associated with micronutrient supplementation, as reported by each included trial. If the trial authors had classified these events according to the Adverse Event Toxicity Scale, we extracted the data accordingly: grade 1 or 2 (mild to moderate symptoms), grade 3 (serious symptoms), or grade 4 symptoms (denotes life‐threatening events that require a significant clinical intervention) (<a href="./references#CD003650-bbs2-0096" title="Division ofAIDS . Table for grading the severity of adult and pediatric adverse events. http://rsc.tech‐res.com/docs/default‐source/safety/daids_ae_grading_table_v2_nov2014.pdf (accessed 16 February 2017). ">DAIDS 2014</a>). </p> </section> </section> </section> </section> <section id="CD003650-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003650-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the CENTRAL (<a href="./appendices#CD003650-sec-0148">Appendix 1</a>), PubMed (<a href="./appendices#CD003650-sec-0149">Appendix 2</a>), and Embase (<a href="./appendices#CD003650-sec-0150">Appendix 3</a>) databases from January 2010 up to 18 November 2016. We limited the search date from January 2010, since <a href="./references#CD003650-bbs2-0126" title="IrlamJ , VisserMME , RollinsNN , SiegfriedN . Micronutrient supplementation in children and adults with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD003650.pub3] ">Irlam 2010</a> included all trials identified from searches prior to and including January 2010. In addition we checked the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="./appendices#CD003650-sec-0151">Appendix 4</a>) and the ClinicalTrials.gov trial register (<a href="./appendices#CD003650-sec-0152">Appendix 5</a>). We also searched the reference lists of the included trials. </p> </section> <section id="CD003650-sec-0048"> <h4 class="title">Searching other resources</h4> <p>For this update, we searched the reference lists of all the included trials. We also contacted investigators of ongoing studies that have been completed by email to enquire about any new or imminent publications. </p> </section> </section> <section id="CD003650-sec-0049"> <h3 class="title" id="CD003650-sec-0049">Data collection and analysis</h3> <section id="CD003650-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MV and SD) independently screened the titles and abstracts identified through the electronic searches for potentially eligible citations for full‐text screening. In the case of uncertainty regarding eligibility, we screened the full‐text article(s). Two review authors (MV and SD) screened full‐text articles using a standardized eligibility form based on the inclusion criteria of the review. In the case of disagreement or uncertainty, a third review author (NS) provided their opinion. We listed all studies that we excluded after full‐text assessment and their reasons for exclusion in a '<a href="./references#CD003650-sec-0168" title="">Characteristics of excluded studies</a>' table. We constructed a PRISMA diagram to illustrate the study selection process. </p> </section> <section id="CD003650-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MV and SD) independently extracted data from the included trials for the review update using an updated standardized electronic data extraction form. We extracted the following information from each trial. </p> <p> <ul id="CD003650-list-0003"> <li> <p>Administrative details: trial identification number; author(s); published or unpublished; year of publication </p> </li> <li> <p>Details of the trial: country and location of trial, trial design, duration and completeness of follow‐up; informed consent and ethics approval, source of funding </p> </li> <li> <p>Details of participants: age, gender, disease progression according to clinical staging, relevant baseline characteristics including CD4 count and viral load </p> </li> <li> <p>Details of intervention and control group: type, dosage, and frequency of micronutrient(s); additional co‐interventions (such as ART, tuberculosis treatment, or other management of opportunistic infections) </p> </li> <li> <p>Details of outcomes: all prespecified outcomes and any additional outcomes reported in the study; adverse events and toxicity </p> </li> <li> <p>Details of data analysis: numbers and reported statistics for each reported outcome. Where trial outcomes were reported in more than one reference, we used all the trial reports to extract data as comprehensively as possible </p> </li> </ul> </p> <p>We entered data into the Review Manager 5 (RevMan 5) software (<a href="./references#CD003650-bbs2-0111" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 5</a>). The trial ID for each included trial consisted of the name of the first trial author followed by the date of publication and the country code where the study was conducted (see <a href="./appendices#CD003650-sec-0153">Appendix 6</a>). </p> </section> <section id="CD003650-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MV and SD) independently assessed the risk of bias of each new included trial using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD003650-bbs2-0102" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Version 5.1.0. The Cochrane Collaboration. ">Higgins 2011</a>). Please see <a href="./appendices#CD003650-sec-0154">Appendix 7</a> for the additional assessment of risk of bias in included cluster‐randomized trials.For each trial we assessed the following domains as either at high, low, or unclear risk of bias: sequence generation, allocation concealment, blinding (participants, personnel, and outcome assessor), incomplete outcome data, selective outcome reporting, and other sources of bias. </p> </section> <section id="CD003650-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>For the measures of treatment effect, we used the risk ratio (RR) for dichotomous data, the weighted mean difference (WMD) for continuous data measured on the same scale, and the standardized mean difference (SMD) for continuous data measured on different scales, presented with 95% confidence intervals (CIs). For time‐to‐event data we extracted the hazard ratio (HR). We used RevMan 5 for data analysis (<a href="./references#CD003650-bbs2-0111" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 5</a>). </p> </section> <section id="CD003650-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>We included two trials with factorial designs (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>). For <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>, we halved the number of events and participants in the placebo group for dichotomous outcomes and the number of participants for continuous outcomes in our meta‐analysis in order to avoid double counting. Since <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> reported time‐to‐event data we were unable to incorporate the data into a meta‐analysis. </p> <p>We described the outcome data narratively for the cross‐over trial by <a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>, since the study authors did not report outcome data before trial cross‐over. For <a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> we did not include the data after trial cross‐over as the trial authors did not clearly describe the wash‐out period. </p> </section> <section id="CD003650-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of three published conference abstracts in order to obtain further information regarding the trial protocol and study outcomes (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; Sales 2010; <a href="./references#CD003650-bbs2-0075" title="ScrimgeourAG , LukaskiHC , PolhemusME , OtienoL , McGrawSM , YoungAJ , et al. Effect of zinc supplementation on diarrhea and malaria morbidity in adults in rural Kenya. FASEB Journal2010;24(1):538.12. ">Scrimgeour 2010</a>). We also contacted other trial authors in order to clarify data or statistical analysis where needed. Where possible, we conducted a complete‐case analysis. For trial outcomes where this was unclear, we used the number of participants randomized to each trial arm. We documented the attrition rate for each included trial in the 'Risk of bias' table. </p> </section> <section id="CD003650-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>First we assessed trials for clinical heterogeneity by examining variability in the participants, interventions, and outcomes. We assessed statistical heterogeneity visually and by means of the Chi² test for heterogeneity and the I² statistic. We classified heterogeneity according to the I² statistic values as follows (<a href="./references#CD003650-bbs2-0101" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>). </p> <p> <ul id="CD003650-list-0004"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> </section> <section id="CD003650-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>To prevent reporting biases we searched multiple sources and searched for unpublished studies in trials registers. We did not examine funnel plots to assess the likelihood of publication bias as there were an insufficient number of trials per outcome. </p> </section> <section id="CD003650-sec-0058"> <h4 class="title">Data synthesis</h4> <p>In view of the anticipated heterogeneity between trial populations and interventions, we used a random‐effects model. When we were unable to pool data due to differences in the statistical methods and measures the study authors used, we presented the data in tables with a narrative summary. </p> </section> <section id="CD003650-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted stratified analyses according to whether participants were taking ART or not, and whether they were on concurrent treatment for tuberculosis or not. We stratified outcome data, such as CD4+ cell count and viral load, by time points (baseline and at longest time follow‐up) in order to demonstrate changes over time. </p> <section id="CD003650-sec-0060"> <h5 class="title">Certainty of the evidence</h5> <p>Two review authors (MV and SD) independently assessed the certainty of the evidence for the outcomes under each comparison (type of micronutrient intervention) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. According to this approach the certainty rating of evidence for each outcome is determined by an assessment of the available study data in terms of its risk of bias, inconsistency, indirectness, imprecision, and publication bias. We used GRADEpro Guideline Development Tool (GDT) software to create 'Summary of findings' tables for each comparison (<a href="./references#CD003650-bbs2-0099" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 01 March 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro 2014</a>). </p> </section> </section> <section id="CD003650-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We could not perform a sensitivity analysis to assess the robustness of the results against the 'Risk of bias' domains as there were too few studies for each comparison. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003650-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003650-sec-0062">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003650-sec-0171">Español</a> </li> </nav> </div> </div> <section class="results" lang="en"> <div class="section-header" id="CD003650-sec-0062"></div> <section id="CD003650-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD003650-sec-0064"> <h4 class="title">Results of the search</h4> <p>The previous version of this review, which included pregnant women and children, included 30 trials (<a href="./references#CD003650-bbs2-0126" title="IrlamJ , VisserMME , RollinsNN , SiegfriedN . Micronutrient supplementation in children and adults with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD003650.pub3] ">Irlam 2010</a>). Only 16 of these were eligible for inclusion in this Cochrane Review. </p> <p>The PRISMA flow diagram summarizes the results of the searches for this update (<a href="#CD003650-fig-0001">Figure 1</a>). Electronic database searches identified 1835 records, of which there were 1572 records after we removed duplicates. After we screened these records by title/abstract, we identified 68 articles for full‐text assessment. Handsearching identified three new trials. Seventeen new trials met the inclusion criteria of this review, which gave a total of 33 included trials. Of the new included trials, four reported outcome data in two articles (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>; <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>), and two letters of correspondence were related to one included trial (<a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>). Two included trials published their trial protocols (<a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>; <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>). We identified one additional trial from our most recent search (18 November 2016), which we included in the '<a href="./references#CD003650-sec-0169" title="">Characteristics of studies awaiting classification</a>' section. We identified six ongoing trials from searching trial registries. </p> <div class="figure" id="CD003650-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD003650-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD003650-sec-0065"> <h4 class="title">Included studies</h4> <section id="CD003650-sec-0066"> <h5 class="title">Participants</h5> <p>Thirteen trials, which included 4493 participants, were conducted in antiretroviral therapy (ART)‐naive participants (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>; <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>; <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>; <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>; <a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>; <a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>; <a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>). One small trial did not state whether participants received ART or not (<a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a>). </p> <p>The remaining 19 trials included 5730 participants, with most receiving either mono‐ or combination ART (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>; <a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>; <a href="./references#CD003650-bbs2-0010" title="CoodleyGO , CoodleyMK , LuskR , GreenTR , BakkeAC , WilsonD , et al. Beta‐carotene in HIV infection: an extended evaluation. AIDS1996;10(9):967‐73. ">Coodley 1996 USA</a>; <a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>; <a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>), or highly active antiretroviral therapy (HAART) (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>; <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0011" title="DoughertyKA , SchallJI , ZemelBS , TulucF , HouX , RutsteinRM , et al. Safety and efficacy of high‐dose daily vitamin D3 supplementation in children and young adults infected with human immunodeficiency virus. Journal of the Paediatric Infectious Diseases Society2014;3(4):294‐303. [DOI: 10.1093/jpids/piu012] ">Dougherty 2015 USA</a>; <a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>; <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>; <a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>; <a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>; <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>; <a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>; <a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>; <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>). Many of these trials were small with fewer than 100 participants, with the exception of <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a> which had more than 3000 participants. </p> <p>In five trials participants were on concurrent treatment for active tuberculosis (<a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>; <a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>). </p> </section> <section id="CD003650-sec-0067"> <h5 class="title">Trial site</h5> <p>Trials were undertaken in the following places.</p> <p> <ul id="CD003650-list-0005"> <li> <p>Africa: Botswana (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>), Kenya (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>; <a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a>), Guinea‐Bissau (<a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>), Malawi (<a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>), Nigeria (<a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>), Rwanda (<a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>), Tanzania (<a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>), Uganda (<a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>), and Zambia (<a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>) </p> </li> <li> <p>Asia: China (<a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a>), Singapore (<a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>), and Thailand (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>) </p> </li> <li> <p>North America: Canada (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>) and USA (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>; <a href="./references#CD003650-bbs2-0010" title="CoodleyGO , CoodleyMK , LuskR , GreenTR , BakkeAC , WilsonD , et al. Beta‐carotene in HIV infection: an extended evaluation. AIDS1996;10(9):967‐73. ">Coodley 1996 USA</a>; <a href="./references#CD003650-bbs2-0011" title="DoughertyKA , SchallJI , ZemelBS , TulucF , HouX , RutsteinRM , et al. Safety and efficacy of high‐dose daily vitamin D3 supplementation in children and young adults infected with human immunodeficiency virus. Journal of the Paediatric Infectious Diseases Society2014;3(4):294‐303. [DOI: 10.1093/jpids/piu012] ">Dougherty 2015 USA</a>; <a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>; <a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>; <a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>; <a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>; <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>) </p> </li> <li> <p>South America: Brazil (<a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>) and Peru (<a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>) </p> </li> <li> <p>Europe: Denmark (<a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>) and Italy (<a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>) </p> </li> </ul> </p> </section> <section id="CD003650-sec-0068"> <h5 class="title">Interventions</h5> <p>Twenty‐nine placebo‐controlled studies met the inclusion criteria. Of these, two had factorial designs (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>). For both of these trials we extracted data for two treatment comparisons. Trials assessed the effectiveness of the supplementation of the following. </p> <p> <ul id="CD003650-list-0006"> <li> <p>Multiple micronutrients (10 trials; 3533 participants: <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>; <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>; <a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>; <a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a>) </p> </li> <li> <p>Vitamin A (4 trials; 581 participants: <a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>; <a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>; <a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>; <a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>) </p> </li> <li> <p>Vitamin D (5 trials; 447 participants: <a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>; <a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>; <a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>; <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>; <a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>) </p> </li> <li> <p>Vitamin E combined with vitamin C (1 trial, 49 participants: <a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>) </p> </li> <li> <p>Folinic acid (1 trial, 30 participants: <a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>) </p> </li> <li> <p>Zinc (6 trials, 826 participants: <a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>; <a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>; <a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>, <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>) </p> </li> <li> <p>Selenium (4 trials, 1308 participants: <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>; <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>) </p> </li> </ul> </p> <p>In addition, we identified four trials that assessed the effectiveness of the supplementation of the following. </p> <p> <ul id="CD003650-list-0007"> <li> <p>High dose versus standard dose multiple micronutrients (<a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>) </p> </li> <li> <p>4000 IU vitamin D versus 7000 IU vitamin D (<a href="./references#CD003650-bbs2-0011" title="DoughertyKA , SchallJI , ZemelBS , TulucF , HouX , RutsteinRM , et al. Safety and efficacy of high‐dose daily vitamin D3 supplementation in children and young adults infected with human immunodeficiency virus. Journal of the Paediatric Infectious Diseases Society2014;3(4):294‐303. [DOI: 10.1093/jpids/piu012] ">Dougherty 2015 USA</a>) </p> </li> <li> <p>Multiple micronutrients with iron versus multiple micronutrients (<a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>) </p> </li> <li> <p>β‐carotene with multivitamins versus multivitamins (<a href="./references#CD003650-bbs2-0010" title="CoodleyGO , CoodleyMK , LuskR , GreenTR , BakkeAC , WilsonD , et al. Beta‐carotene in HIV infection: an extended evaluation. AIDS1996;10(9):967‐73. ">Coodley 1996 USA</a>) </p> </li> </ul> </p> <p>The follow‐up periods of these trials ranged from two weeks to 24 months.</p> </section> <section id="CD003650-sec-0069"> <h5 class="title">Sample size</h5> <p>Trials were generally underpowered to demonstrate effects on mortality. For example, to demonstrate a 25% reduction in deaths of HIV‐positive participants not on ART 2412 trial participants would be required, and to identify the same reduction for those on ART 7314 trial participants would be required (<a href="#CD003650-tbl-0006">Table 1</a>). This far exceeds the number of participants in the three included trials that reported on this outcome (<a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>). <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a> based their sample calculation of 3000 participants on the basis of a 25% reduction in the composite outcome of death and disease progression (any new or recurrent AIDS‐defining illness). We have provided the optimal information sizes for nutritional outcomes in <a href="#CD003650-tbl-0007">Table 2</a>. </p> <div class="table" id="CD003650-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Optimal information size calculations (dichotomous outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Power</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Two‐sided significance level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk in intervention group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size (total)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2412</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3%<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4782</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5%<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7314</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 cell count ≤ 350 cells/mm<sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2312</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 cell count ≤ 350 cells/mm<sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 cell count ≤ 350 cells/mm<sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Estimated annual risk of death of antiretroviral naive HIV‐infected persons (≥10 years after seroconversion) (<a href="./references#CD003650-bbs2-0095" title="Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV‐1 seroconversion to AIDS and death before widespread use of highly‐active antiretroviral therapy: a collaborative re‐analysis. Lancet2000;355(9210):1131‐7. ">Collaborative Group on AIDS Incubation 2000</a>).<br/> <sup>2</sup>Estimated annual risk of death of antiretroviral naive HIV‐infected persons (5 to 9 years after seroconversion) (<a href="./references#CD003650-bbs2-0095" title="Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV‐1 seroconversion to AIDS and death before widespread use of highly‐active antiretroviral therapy: a collaborative re‐analysis. Lancet2000;355(9210):1131‐7. ">Collaborative Group on AIDS Incubation 2000</a>).<br/> <sup>3</sup>Estimated risk of death of HIV‐infected persons after receiving first‐line antiretroviral therapy regimens for 12 months (<a href="./references#CD003650-bbs2-0108" title="MbuagbawLCE , IrlamJH , SpauldingA , RutherfordGW , SiegfriedN . Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD004246.pub3] ">Mbuagbaw 2010</a>).<br/> <sup>4</sup>Antiretroviral naive HIV‐infected participants who experience a decline in CD4 count (Kamwesiga 2011a, which is under <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>). </p> </div> </div> <div class="table" id="CD003650-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Optimal information size calculations (continuous outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Power</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Two‐sided significance level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ratio of group 1: group 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean in supplement group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size (total)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean blood 25(OH) vitamin D level at 12 months<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean blood 25(OH) vitamin D level at 12 months<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BMI at 24 months<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BMI at 24 months <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: BMI: body mass index; SD: standard deviation.</p> <p><sup>1</sup>This example is based on data from <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>. This example uses the SD from the control group.<br/> <sup>2</sup>This example is based on data from <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>. This example uses the SD from the supplemented group.<br/> <sup>3</sup>This example uses the SD from <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>, but uses a 1 kg/m<sup>2</sup> mean difference for illustrative purposes.<br/> <sup>4</sup>This example uses the SD from <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>, but uses a 2 kg/m<sup>2</sup> mean difference for illustrative purposes. </p> </div> </div> <p>For full details of the included studies refer to the '<a href="./references#CD003650-sec-0167" title="">Characteristics of included studies</a>' section. </p> </section> </section> <section id="CD003650-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 trials that were included in the previous version of this review, <a href="./references#CD003650-bbs2-0126" title="IrlamJ , VisserMME , RollinsNN , SiegfriedN . Micronutrient supplementation in children and adults with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD003650.pub3] ">Irlam 2010</a>, from the current version. Eight trials were in HIV‐positive children; four trials were in HIV‐positive pregnant women; and in two trials the study participants received micronutrient supplements that did not contain micronutrients exclusively (<a href="./references#CD003650-bbs2-0037" title="AustinJ , SinghalN , VoigtR , SmaillF , GillMJ , WalmsleyS , et al. A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome. European Journal of Clinical Nutrition2006;60(11):1266‐76. ">Austin 2006</a>; <a href="./references#CD003650-bbs2-0054" title="KaiserJD , CampaAM , OndercinJP , LeoungGS , PlessRF , BaumMK . Micronutrient supplementation increases CD4 count in HIV‐infected individuals on highly active antiretroviral therapy: A prospective, double‐blinded, placebo‐controlled trial. Journal of Acquired Immune Deficiency Syndromes2006;42(5):523‐8. ">Kaiser 2006</a>). </p> <p>We excluded 46 records after full‐text assessment, 13 of which were not RCTs. We excluded the remaining studies because they addressed interventions that were not exclusively micronutrients (n = 10), had a co‐intervention (n = 4), involved trial participants aged less than 15 years (n = 4) or those with HAART co‐morbidity (n = 3), or reported study outcomes not relevant to this review (n = 12) (<a href="#CD003650-fig-0001">Figure 1</a>). </p> <p>See the '<a href="./references#CD003650-sec-0168" title="">Characteristics of excluded studies</a>' table. </p> </section> </section> <section id="CD003650-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>We evaluated the risk of bias of included studies for each of the six domains in the <a href="#CD003650-sec-0037">Methods</a> section above (see the '<a href="./references#CD003650-sec-0167" title="">Characteristics of included studies</a>' table). <a href="#CD003650-fig-0002">Figure 2</a> and <a href="#CD003650-fig-0003">Figure 3</a> present a graphical summary of the 'Risk of bias' assessments. </p> <div class="figure" id="CD003650-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD003650-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003650-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD003650-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD003650-sec-0072"> <h4 class="title">Allocation</h4> <p>Overall 20 trials adequately described a low risk method of random sequence generation. In 13 trials the methods were unclear. Fourteen trials adequately described a method of allocation concealment, and in 19 the methods were unclear. </p> </section> <section id="CD003650-sec-0073"> <h4 class="title">Blinding</h4> <p>Blinding of participants, treatment providers and outcome assessors was well described in 25 trials, which we judged to be at low risk of detection and performance bias. The remaining trials were at unclear risk except <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>, which we considered to be high risk due to the use of a non‐identical placebo. The main reason for trials being at unclear risk was that no information was provided about the blinding of the investigators or outcome assessors. </p> </section> <section id="CD003650-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 14 trials to be at high risk of attrition bias due to incomplete outcome data. In two trials this risk only applied to the measures of viral load which were only reported on a subset of trial participants (<a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>). Eleven trials had high attrition overall or differential attrition, or both (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>; <a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>; <a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>; <a href="./references#CD003650-bbs2-0010" title="CoodleyGO , CoodleyMK , LuskR , GreenTR , BakkeAC , WilsonD , et al. Beta‐carotene in HIV infection: an extended evaluation. AIDS1996;10(9):967‐73. ">Coodley 1996 USA</a>; <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>; <a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>), and in <a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a> participants lost to follow‐up had more advanced HIV disease and vitamin A deficiency. Thus we considered these trials to be at high risk for attrition bias. </p> </section> <section id="CD003650-sec-0075"> <h4 class="title">Selective reporting</h4> <p>Insufficient information was available to permit judgment about the extent of bias due to selective outcome reporting in all but 11 included studies. We judged 10 of these as at low risk (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>; <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>; <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>; <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>; <a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>; <a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>; <a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>), and one as at high risk of reporting bias (<a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). </p> </section> <section id="CD003650-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>One trial was stopped early due to evidence of increased alanine transaminase (ALT) levels with the intervention (<a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>). </p> <p>Fourteen trials did not declare potential conflicts of interest (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>; <a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>; <a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>; <a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>; <a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>; <a href="./references#CD003650-bbs2-0010" title="CoodleyGO , CoodleyMK , LuskR , GreenTR , BakkeAC , WilsonD , et al. Beta‐carotene in HIV infection: an extended evaluation. AIDS1996;10(9):967‐73. ">Coodley 1996 USA</a>; <a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>; <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>; <a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a>; <a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>). </p> <p>All but 19 trials were funded either fully or partly from government sources (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>; <a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>; <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>; <a href="./references#CD003650-bbs2-0010" title="CoodleyGO , CoodleyMK , LuskR , GreenTR , BakkeAC , WilsonD , et al. Beta‐carotene in HIV infection: an extended evaluation. AIDS1996;10(9):967‐73. ">Coodley 1996 USA</a>; <a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>; <a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>; <a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>; <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>; <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a>; <a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>; <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>); five were fully or partly funded by pharmaceutical companies (<a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>; <a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>; <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>); and one trial did not provide the source of funding (<a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a>). </p> </section> </section> <section id="CD003650-sec-0077"> <h3 class="title" id="CD003650-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD003650-tbl-0001"><b>Summary of findings for the main comparison</b> Multiple micronutrients compared to placebo for adults with HIV infection</a>; <a href="./full#CD003650-tbl-0002"><b>Summary of findings 2</b> Vitamin A compared to placebo</a>; <a href="./full#CD003650-tbl-0003"><b>Summary of findings 3</b> Vitamin D compared to placebo</a>; <a href="./full#CD003650-tbl-0004"><b>Summary of findings 4</b> Zinc compared to placebo</a>; <a href="./full#CD003650-tbl-0005"><b>Summary of findings 5</b> Selenium compared to placebo</a> </p> <section id="CD003650-sec-0078"> <h4 class="title">Comparison 1: Multiple micronutrients versus placebo</h4> <p>Ten trials compared a daily multiple micronutrient supplement to placebo, given for between two weeks and two years (see <a href="#CD003650-tbl-0008">Table 3</a>). Most participants were ART‐naive HIV‐positive adults, and in three trials all participants were on treatment for active pulmonary tuberculosis. Only <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a> recruited people already taking ART (49.8% of trial participants), and the remaining participants were commenced on ART at the start of this trial. Trials were conducted in Africa (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>; <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>; <a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>), Thailand (<a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>), and China (<a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a>). </p> <div class="table" id="CD003650-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of trials evaluating multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline HAART use (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load</b> </p> <p><b>(copies/ml or log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMN dose<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botswana</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,800 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uganda</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.8<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (median)</p> <p>137 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus chronic diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 years<sup>4</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kenya</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (209)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (69)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363 (275)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.02 (0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malawi</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months<sup>5</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (227)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: HAART: highly active antiretroviral therapy; MMN: multiple micronutrient; TB: Tuberculosis </p> <p><sup>1</sup>Standard dose supplements provided most of the micronutrients at the level of the Dietary Recommended Intake (DRI). High‐dose supplements provided most of the micronutrients in multiples of the DRI.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>: participants who received ART for no longer than 6 months. The rest of the trial participants were initiated on ART at baseline.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>: we excluded participants taking HAART from the analysis of CD4 and viral load.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> was a cross‐over trial, with cross‐over at the end of 1.9 years. We did not include the outcome data for the period after cross‐over.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>: the median duration of follow‐up was 12.5 months, due to the introduction of ART programme. </p> </div> </div> <p>Four trials evaluated multiple micronutrient supplements in doses consistent with the Recommended Daily Intake (RDA) (standard dose supplements), and six trials used substantially higher doses (high dose supplements). In summary, high dose supplements included: vitamin A (2 to 3 x RDA), B vitamins (6 to 20 x RDA), vitamin C (3 to 5 times x RDA), vitamin D (1 x RDA), Vitamin E (2 to 20 x RDA), selenium (2 to 7 x RDA), and zinc (2 to 4 x RDA) (see <a href="#CD003650-tbl-0009">Table 4</a>). </p> <div class="table" id="CD003650-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Composition of multiple micronutrient supplements</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Micronutrient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> RDA male aged 19 to 70 years</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Standard doses<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>High doses<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Standard dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> High dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. "><b>Kelly 2008 ZMB</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. "><b>Zhao 2010 CHN</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. "><b>Semba 2007 MWI</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. "><b>Guwatudde 2015 UG</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. "><b>Baum 2013 BWA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. "><b>Kelly 1999 ZMB</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. "><b>Jiamton 2003 THA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. "><b>McClelland 2004 KEN</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. "><b>Range 2006 TZA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. "><b>Villamor 2008 TZA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. "><b>Isanaka 2012 TZA</b> </a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 µg<br/> (3000 IU) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg (660 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2424µg (8000 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3182 µg (10500 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3027 µg (9990 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 µg (5000 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1515 µg (5000 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B‐carotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B1 (Thiamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B2 (riboflavin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B3 (niacin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B6 (pyridoxine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 to 1.7 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B9<br/> (folinic acid) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5000 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panthothenic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15 µg (200 to 600 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 µg (200 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 µg (200 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 µg (400 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 µg (800 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 µg (200 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Copper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chromium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Manganese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: IU: International units; RDA:Recommended Daily Allowance</p> <p><sup>1</sup>Standard dose supplements provided most of the micronutrients at the level of the RDA.<br/> <sup>2</sup>High‐dose supplements provided most of the micronutrients in multiples of the RDA. </p> </div> </div> <p>Of the ten trials, we judged four to be at low risk of selection bias (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>, <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>), and we considered seven to be at low risk of performance and detection bias as they adequately described blinding (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>; <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>; <a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>). </p> <section id="CD003650-sec-0079"> <h5 class="title">Mortality</h5> <p>Overall, statistically significant differences on mortality were not demonstrated, but the trials were substantially underpowered to confidently detect or exclude small but clinically important effects (risk ratio (RR) 0.91, 95% confidence interval (CI) 0.72 to 1.15; 7 trials, 2897 participants, <a href="./references#CD003650-fig-0004" title="">Analysis 1.1</a>). </p> <p> <ul id="CD003650-list-0008"> <li> <p>In three trials in ART‐naive adults, although the proportion of deaths was lower with supplementation, the 95% confidence interval (CI) was wide and included the possibility of both clinically important effects and no effect (RR 0.60, 95% CI 0.31 to 1.15; 3 trials, 1068 participants; I² statistic = 0%). One additional small trial from Zambia, with only four weeks follow‐up, also reported no difference in mortality but did not present data that we could include in the meta‐analysis (<a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>). </p> </li> <li> <p>In the only trial in adults on ART, <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>, the proportion of deaths was similar in both treatment arms, and the 95% CI was very wide (RR 1.25, 95% CI 0.50 to 3.10; 1 trial, 400 participants). </p> </li> <li> <p>In three trials in adults on treatment for active tuberculosis (and also not on ART), although the CI was narrower, there was no effect of supplementation on mortality (RR 0.92, 95% CI 0.69 to 1.23; 3 trials, 1429 participants; I² statistic = 54%). One small factorial trial from Tanzania, <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>, found a statistically significant effect in a subgroup of HIV‐positive participants who received multiple micronutrients plus zinc, but the CI was wide and the trial was underpowered (RR 0.29, 95% CI 0.09 to 0.87; 1 trial, 84 participants). A positive result in an underpowered study is not likely to reflect a true result (low positive predictive value (PPV)) and the magnitude of the effect estimate may also be exaggerated (<a href="./references#CD003650-bbs2-0093" title="ButtonKS , LoannidisJPA , MokryszC , NosekBA , FlintJ , RobinsonES , et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews. Neuroscience2013;14(5):365‐76. ">Button 2013</a>). Furthermore, the trial authors reported differential attrition between treatment groups. </p> </li> </ul> </p> </section> <section id="CD003650-sec-0080"> <h5 class="title">Morbidity and clinical disease progression</h5> <p>Two trials reported the risk of hospital admission, and although this was lower with multiple micronutrient supplementation, the CIs were wide and included both clinically important benefits and harms (RR 0.86, 95% CI 0.61 to 1.22; 2 trials, 881 participants, <a href="./references#CD003650-fig-0005" title="">Analysis 1.2</a>). In one trial, <a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>, participants commenced ART at the start of the trial and in the second trial, <a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>, participants were not on ART. </p> <p>One additional trial in people on treatment for tuberculosis reported no difference in the risk of clinical disease progression (hazard ratio (HR) 1.08 95% CI 0.72 to 1.62; 1 trial, 313 participants, <a href="./references#CD003650-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD003650-sec-0081"> <h5 class="title">Virological and immunological outcomes</h5> <p>Nine trials reported changes in CD4+ count over periods from four weeks to two years (see <a href="#CD003650-tbl-0010">Table 5</a>). We could not incorporate one additional trial from Botswana that reported time‐to‐event analyses (time to reach CD4+ count &lt; 250 cells/mm³) into the meta‐analyses (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>). </p> <div class="table" id="CD003650-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (86 to 215)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137 (68 to 192)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐ 6.17 (95% CI ‐29.3 to 16.9)<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244 (52 to 544)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (66 to 358)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261 (50 to 550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 (73 to 377)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Did not differ"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not different"<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 (190)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>415 (242)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (212)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409 (192)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 years<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (209)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 (205)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (202)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265 (189)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted regression co‐efficient 23 (95% CI 3 to 43); P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>589 (85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466 (72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 (391)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (373)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 (385)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>403 (460)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (277)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339 (256)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 (240)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5 (−37 to 26); P = 0.74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 (336 to 555)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411 (327 to 545)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>7</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: IQR: Interquartile range; MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for end‐point data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>: the trial authors reported a mean difference which is different to our calculation. The reasons for this are unclear.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>: the trial authors did not report data that we could include in a meta‐analysis.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> was a cross‐over trial, with cross‐over at the end of 1.9 years. CD4+ counts were recorded during the second year of follow‐up. The data for the period after cross‐over is not included in this table.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>: data shown are for multiple micronutrients plus zinc versus placebo. There were also no differences for micronutrients without zinc versus placebo.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> also reported outcomes at 8 months, with no significant difference between groups.<br/> <sup>7</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: data shown are for multivitamins plus selenium versus placebo. The trial authors reported reductions in the risk of CD4+ falling to &lt; 250 cells/µL for multivitamins plus selenium versus placebo (HR 0.48, 95% CI 0.26 to 0.88 ) and for multivitamins alone versus placebo (HR 0.54, 95% CI 0.3 to 0.98). Multivariate analysis showed that this effect was only apparent with supplementation of both multivitamins and selenium (HR 0.46, 95% CI 0.25 to 0.85). </p> </div> </div> <p> <ul id="CD003650-list-0009"> <li> <p>Six trials reported data as means with standard deviation (SD) and the pooled effect had a wide 95% CI including modest benefits and harms (mean difference (MD) 24.79, 95% CI −23.54 to 73.12; 6 trials, 1581 participants; <a href="./references#CD003650-fig-0007" title="">Analysis 1.4</a>, <a href="./references#CD003650-fig-0008" title="">Analysis 1.5</a>). Only one small trial from China administering multiple micronutrients at around the daily recommended intake, reported a statistically significant effect with supplementation after six months (1 trial, 99 participants, <a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a>). The other much larger trials that administered higher doses of multiple micronutrients found no suggestion of effects; including 808 participants with HIV alone, and 674 participants with HIV plus active tuberculosis </p> </li> <li> <p>Three trials reported data as medians and interquartile range (IQR), and neither found a statistically significant result (3 trials, 911 participants, data not pooled, <a href="#CD003650-tbl-0010">Table 5</a>) </p> </li> <li> <p>One additional trial from Botswana reported data as the HR of reaching a CD4+ count of less than 250 cells/mm³. The hazard was lower with high dose supplements of multivitamins plus selenium for two years (HR 0.48, 95% CI 0.26 to 0.88; 1 trial, 439 participants) and with multivitamins alone (HR 0.54; 95% CI 0.3 to 0.98; 1 trial, 436 participants) However, the trial authors reported that this effect was only apparent with supplementation of both multivitamins and selenium after adjustment for multiple confounders (HR 0.46, 95% CI 0.25 to 0.85; 1 trial, 439 participants) (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>) </p> </li> </ul> </p> <p>Five trials of high dose multiple micronutrients reported changes in viral load at time points from six weeks to two years (see <a href="#CD003650-tbl-0011">Table 6</a>). </p> <div class="table" id="CD003650-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Change in viral load (log10 copies/mL): multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (3.3‐4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3 (3.6 to 4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.4<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.72 (1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.85 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not significant"<sup>5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.74 (1.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −0.08 (−0.22 to 0.05); P = 0.23</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: Confidence interval; IQR: Interquartile range; MD: Mean difference; SD: Standard deviation </p> <p><sup>1</sup>The number of participants stated is the number assessed for end‐point data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: multiple imputation of viral load data was performed. The trial authors did not provide details.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: data shown are for multivitamins plus selenium versus placebo. There were also no differences for multivitamins without selenium versus placebo.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>: viral load analyses was conducted on the first 140 consecutive participants (29% of participants).<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>: data shown are for multiple micronutrients plus zinc versus placebo. There were also no differences for micronutrients without zinc versus placebo.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> also reported outcomes at 8 months, with no significant difference between groups. </p> </div> </div> <p> <ul id="CD003650-list-0010"> <li> <p>Four trials reported data as means with SDs and the pooled estimate was close to no effect with a CI which included a modest benefit and no effect (MD −0.10, 95% CI −0.25 to 0.05; 4 trials, 1064 participants; <a href="./references#CD003650-fig-0009" title="">Analysis 1.6</a>,<a href="./references#CD003650-fig-0010" title="">Analysis 1.7</a>) </p> </li> <li> <p>The fifth trial reported no effect on viral load in a multivariable random‐effects regression model (1 trial, 437 participants, P = 0.4) (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>) </p> </li> </ul> </p> </section> <section id="CD003650-sec-0082"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>Three trials reported changes in measures of body composition (BMI, weight, mid‐upper arm circumference (MUAC), fat mass or lean body mass) with no statistically significant differences between groups (see <a href="#CD003650-tbl-0012">Table 7</a>). </p> <div class="table" id="CD003650-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Change in nutritional status parameters: multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint<br/> (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.3 (2.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.2</p> <p>(3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.1</p> <p>(−0.4 to 0.2); P = 0.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight (kg)</p> <p>Haemoglobin (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>12.2 (11.2 to 13.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>12.3 (11.3 to 13.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.54 (−0.40 to 1.48); P = 0.691</p> <p>MD 0.16 (−0.21 to 0.16);</p> <p>P = 0.977</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003</a><sup>12</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin E (µmol/L)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.7 (7.0 to 14.3)<sup>4</sup>; P &lt; 0.001 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µmol/L)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.16 (0.0 to 0.34)<sup>6</sup>; P = 0.04 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a><sup>12</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin A (µmol/L)<sup>7,8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin E (µmol/L)<sup>3,8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No difference"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> <p>MUAC (cm)</p> <p>Fat mass (kg)</p> <p>Lean body mass (kg)</p> <p>Grip strength (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 years <sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant differences at any time point"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a><sup>12</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin A (µmol/L)<sup>7,11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geometric mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Significantly higher"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µmol/L)<sup>10,11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geometric mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: BMI: Body Mass Index; IQR: Interquartile range; MUAC: Mid‐upper arm circumference; MD: Mean difference; SD: Standard deviation </p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> also reported outcomes at 8 months, with no significant difference between groups (MD 0, 95% CI −0.2 to 0.3; P = 0.74).<br/> <sup>3</sup>Reference value for vitamin E sufficiency ≥ 11.6 µmol/L.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>: the trial authors reported endpoint data on a subset of 44 participants. The trial authors did not state the number of participants for each treatment group. Baseline vitamin E levels (µmol/L) reported for 112 participants.<br/> <sup>5</sup>Reference value for selenium sufficiency: ≥ 0.95 µmol/L.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>: the trial authors reported endpoint data on a subset of 54 participants. The number of participants for each treatment group is not stated. Baseline selenium levels (µmol/L) reported for 129 participants.<br/> <sup>7</sup>Reference value for vitamin A deficiency: &lt; 0.7 µmol/L.<br/> <sup>8</sup><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>: the trial authors reported that 67% and 55% of participants were deficient in vitamins A and E, respectively, at baseline.<br/> <sup>9</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> was a cross‐over trial, with cross‐over at the end of 1.9 years.<br/> <sup>10</sup>Reference value for selenium sufficiency: ≥ 0.75 µmol/L.<br/> <sup>11</sup><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>: the trial authors reported that 60% and 75% of participants were deficient in vitamin A and selenium respectively, at baseline.<br/> <sup>12</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. </p> </div> </div> <p>Three trials reported changes in blood concentrations of vitamin A, vitamin E, or selenium (see <a href="#CD003650-tbl-0012">Table 7</a>), with statistically significant increases after 48 weeks supplementation in Thailand (<a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>), and eight months supplementation in Malawi (<a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>). The third small trial from Zambia reported no change in serum vitamin A or vitamin E concentrations after four weeks supplementation, despite many being deficient in one or both at baseline (1 trial, 135 participants, <a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>). </p> </section> <section id="CD003650-sec-0083"> <h5 class="title">Adverse events associated with supplementation</h5> <p>One trial with high dose micronutrient supplements reported no differences in serious adverse events such as acute diarrhoea, vomiting, or severely elevated ALT levels (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>). Genital HIV‐shedding was increased after six weeks, following high dose supplements in another trial (<a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a>). A third trial of high dose supplementation reported discolouration of urine more frequently in the intervention group, but no differences for other minor adverse events such as nausea, headache, dizziness, drowsiness, or rash (<a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>). Three trials that involved high dose supplementation did not report any adverse events (<a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>). </p> <p>High dose supplements was associated with a decrease in peripheral neuropathy in one trial, although this was not reported for just the subgroup with HIV (RR 57%, 95% CI 41% to 69%; 1 trial, 887 participants) (<a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>). Participants in this trial were taking isoniazid for active tuberculosis which is a known vitamin B6 antagonist and may cause neuropathy without supplementation. </p> <p>One trial with standard dose supplements reported no differences in adverse events such as nausea and vomiting (<a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>). A cluster‐randomized trial with standard dose supplements reported four cases of pellagra in the placebo group (three were associated with high ethanol intakes) (<a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>). Two trials that involved standard dose supplementation did not report any adverse events (<a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>; <a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a>). </p> </section> <section id="CD003650-sec-0084"> <h5 class="title">Certainty of the evidence</h5> <p>For a critical appraisal of the summary of evidence, see the 'Summary of findings for the main comparison' table (<a href="./full#CD003650-tbl-0001">summary of findings Table for the main comparison</a>) and Additional tables 8, 9, and 10 for the stratified analyses (participants taking ART or not, and whether they were on concurrent treatment for tuberculosis or not) (<a href="#CD003650-tbl-0013">Table 8</a>; <a href="#CD003650-tbl-0014">Table 9</a>; <a href="#CD003650-tbl-0015">Table 10</a>). </p> <div class="table" id="CD003650-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection not currently taking ART<br/> <b>Settings:</b> all settings<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard or high dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (14 to 52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.31 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1068<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may reduce mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> <p>(35 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p>(0.42 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>481</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on hospital admissions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 6 weeks to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>265 to 409 cells/mm</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient group was</p> <p><b>30.36 cells/mm</b> ³ <b>higher</b> </p> <p>(7.13 lower to 67.84 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,6,7</sup> </p> <p>due to indirectness and inconsistency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on CD4+ cell count</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> <p>Follow‐up: 6 to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>4.4 to 5.3 log<sub>10</sub>copies/mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.10 log<sub>10</sub>copies/mL lower</b> </p> <p>(0.27 lower to 0.07 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497</p> <p>(2 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients probably have little or no effect on viral load</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI</b> (kg/m²) </p> <p>Follow‐up: 1.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,9,10</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on BMI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; BMI: body mass index; CI: confidence interval; MUAC: mid‐upper arm circumference; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: all trials were at low risk of selection bias. Appropriate methods of blinding were used.<br/> <sup>2</sup>No serious heterogeneity: none of the trials found statistically significant effects.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: the three trials were conducted in Botswana (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>), Zambia (<a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>) and Thailand (<a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>).The finding of no effect may not apply to all populations.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important effects and no effect. The overall meta‐analysis is substantially underpowered to confidently exclude effects.<br/> <sup>5</sup>Downgraded by 2 for very serious indirectness: only a single trial is available from Thailand (<a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>). The finding of no effect is not easily generalized to other settings.<br/> <sup>6</sup>Downgraded by 1 for serious inconsistency: One trial in Botswana among ART‐naive adults (not included in the meta‐analysis) reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation. This finding is inconsistent with other trials that used similar combinations of micronutrients and selenium.<br/> <sup>7</sup>Downgraded by 1 for serious indirectness: these two trials both used high‐dose multiple micronutrients and were conducted in Kenya (with 6 weeks follow‐up) and Zambia (with 1.9 years follow‐up). TThe finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>8</sup>Downgraded by 1 for serious indirectness: these two studies both used high dose multiple micronutrients and were conducted in Kenya (with 6 weeks follow‐up) and Thailand (with 48 weeks follow‐up). The finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>9</sup>Downgraded by 2 for very serious indirectness: only a single trial from Zambia (<a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>) reports measures of nutritional status. This does not exclude the possibility of effects in some populations.<br/> <sup>10</sup>Downgraded by 1 for serious imprecision: this trial is underpowered to detect or exclude clinically important differences. The trial reported no difference in BMI, mid‐upper arm circumference (MUAC), lean body mass or fat mass but did not present data. </p> </div> </div> <div class="table" id="CD003650-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection currently taking ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (20 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1,25</b> </p> <p>(0.50 to 3.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>195 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (115 to 265) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> </p> <p>(0.59 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on mortality</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was <b>147 cells/mm</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the multiple micronutrient group was <b>6.17 cells/mm</b> ³<b>lower</b> </p> <p>(29.3 lower to 16.9 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>_</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on CD4 cell count</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight</b> (kg) </p> <p>Follow‐up: 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was <b>3.3 kg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the multiple micronutrient group was <b>0.54 kg higher</b> </p> <p>(0.40 lower to 1.48 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on weight</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; HR: hazard ratio; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: this trial was at low risk of selection bias. The trial authors used appropriate methods of blinding.<br/> <sup>2</sup>Downgraded by 2 for serious indirectness: this single trial was conducted in Uganda and administered standard dose multiple micronutrients for two years. The finding of no effect may not be applicable to higher dose or the populations or settings.<br/> <sup>3</sup>Downgraded by 2 for serious imprecision: this single trial is significantly underpowered to confidently detect or exclude effects.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes what may be clinically important effects and no effect. </p> </div> </div> <div class="table" id="CD003650-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis not currently taking ART</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection and concurrent active tuberculosis not currently taking ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard or high dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 8 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> <br/> (246 to 439) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.69 to 1.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2.3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical disease progression from stage 3 to stage 4</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.08</b> (0.72 to 1.62 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on clinical disease progression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 2 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>340 to 403 cells/mm</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient group was</p> <p><b>5.77 cells/mm</b> ³ <b>lower</b> </p> <p>(55.8 lower to 44.25 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>674<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have no effect on CD4 cell count</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> <p>Follow‐up: 2 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>4.1 to 4.7 log<sub>10</sub>copies/mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.09 log<sub>10</sub>copies/mL lower</b> </p> <p>(0.45 lower to 0.26 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343</p> <p>(2 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have no effect on viral load</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BMI in the placebo group was <b>21.2 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BMI in the micronutrient group was</p> <p><b>0.1 lower</b> </p> <p>(0.4 lower to 0.2 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on BMI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; CI: confidence interval; HR: hazard ratio; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: the trials were at low risk of selection bias, except for two trials that recruited both HIV‐positive and HIV‐negative participants and did not stratify the randomization (<a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>). The trials used appropriate methods of blinding.<br/> <sup>2</sup>No serious heterogeneity: one small subgroup of a trial in Tanzania did find a statistically significant difference (<a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>), but larger trials did not.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: the three trials were conducted in Tanzania and Malawi and most patients were not taking ART. The finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes clinically important effects and no effect.<br/> <sup>5</sup>Downgraded by 2 for serious indirectness: data is provided by a single trial from Tanzania and participants were not on antiretroviral therapy (ART). </p> </div> </div> </section> </section> <section id="CD003650-sec-0085"> <h4 class="title">Comparison 2: High‐dose versus standard dose multivitamins</h4> <p>One large Tanzanian trial, <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>, investigated the effects of a standard versus a high‐dose daily multivitamin supplement for 24 months among participants starting HAART (see <a href="#CD003650-tbl-0009">Table 4</a>). </p> <section id="CD003650-sec-0086"> <h5 class="title">Mortality</h5> <p>There were no statistically significant differences in all‐cause mortality (RR 1.06, 95% CI 0.89 to 1.26; 1 trial, 3418 participants; <a href="./references#CD003650-fig-0011" title="">Analysis 2.1</a>), or AIDS‐related mortality (RR 1.14, 95% CI 0.82 to 1.58; 1 trial, 3418 participants; <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>). </p> </section> <section id="CD003650-sec-0087"> <h5 class="title">Morbidity and clinical disease progression</h5> <p>There was no difference in clinical disease progression events combined with death from any cause (RR 1.00, 95% CI 0.96 to 1.04; 1 trial, 3418 participants). </p> </section> <section id="CD003650-sec-0088"> <h5 class="title">Immunological and virological outcomes</h5> <p>There was a small difference between groups in mean CD4+ cell count at baseline (MD −7.00 cells/mm³, 95% CI −13.74 to −0.26), and a similar difference at 15 months (MD −12.00 cells/mm³, 95% CI −24.00 to −0.00; 1 trial, 3418 participants, <a href="./references#CD003650-fig-0012" title="">Analysis 2.2</a>). No differences were demonstrated in mean viral load at baseline or end of follow‐up (MD −0.20 log<sub>10</sub>copies/mL, 95% CI −0.51 to 0.11; 1 trial, 236 participants, <a href="./references#CD003650-fig-0013" title="">Analysis 2.3</a>; <a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. ">Isanaka 2012 TZA</a>). </p> </section> <section id="CD003650-sec-0089"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>There was no difference in BMI between the two groups (MD 0 kg/m<sup>2</sup>; 95% CI −0.2 to 0.2; 1 trial, 3418 participants). Blood concentrations of micronutrients were not reported. </p> </section> <section id="CD003650-sec-0090"> <h5 class="title">Adverse events associated with supplementation</h5> <p>This trial was stopped early with a median length of follow‐up of 15 months due to an increased risk of elevated ALT levels (greater than 40 IU/L) among trial participants who received high dose multivitamin supplements (incidence rate ratio (IRR) 1.44, 95% CI 1.11 to 1.87; one trial, 2921 participants). No differences were observed for other adverse events such as fatigue, nausea or vomiting, diarrhoea, severe anaemia, and rashes or lesions. The incidence of peripheral neuropathy was lower with high dose supplements (IRR 0.81, 95% CI 0.7 to 0.94; 1 trial, 3418 participants). </p> </section> </section> <section id="CD003650-sec-0091"> <h4 class="title">Comparison 3: Vitamin A versus placebo</h4> <p>Four trials compared a vitamin A supplement to placebo (see <a href="#CD003650-tbl-0016">Table 11</a>). Participants from two trials in the USA received a single high dose of vitamin A (200,000 IU to 300,000 IU) and were followed up for four to eight weeks (<a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>; <a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>). ART‐naive women in one trial from Kenya received a daily dose of vitamin A (10,000 IU) for six weeks (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>). The trial authors of a small cross‐over trial of daily supplements containing a vitamin A precursor (β‐carotene) did not report data before cross‐over (<a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>). </p> <div class="table" id="CD003650-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Characteristics of trials evaluating vitamin A supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood vitamin A concentration (µmol/L)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.097 (median)</p> <p>0.095 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 (median)</p> <p>203 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.34 (median)</p> <p>5.54 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,000 IU retinol daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.42)</p> <p>1.41 (0.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300,000 IU retinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive IDUs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61</p> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296 (median)</p> <p>259 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.49 (median)</p> <p>9.67 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200,000 IU retinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 mg β‐carotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: IDUs: Injection drug users; IU: International units; RDA: Recommended Daily Allowance </p> <p><sup>1</sup>Reference value for vitamin A sufficiency: &gt; 1.05 µmol/L.<br/> <sup>2</sup>RDA for a male aged 19 to 70 years is 900 µg (3000 IU) daily.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a> was a cross‐over trial, with cross‐over at the end of 4 weeks. The baseline and outcome data is not reported for the period before cross‐over and therefore we could not include it. </p> </div> </div> <p>Of the four trials, we judged one to be at low risk of selection bias (<a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>), and all four that adequately described blinding and were at low risk of performance and detection bias. </p> <section id="CD003650-sec-0092"> <h5 class="title">Mortality, morbidity, and clinical disease progression</h5> <p>The trials did not report these outcomes.</p> </section> <section id="CD003650-sec-0093"> <h5 class="title">Immunological and virological outcomes</h5> <p>Two trials reported changes in CD4+ count at four and six weeks follow‐up, and neither reported statistically significant changes (2 trials, 464 participants, data not pooled, see <a href="#CD003650-tbl-0017">Table 12</a>). One trial did report that mean CD4+ count was higher in the supplemented group after six weeks (P = 0.04), but the difference was no longer statistically significant after multivariate linear regression analysis (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>). </p> <div class="table" id="CD003650-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): vitamin A versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of end‐point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at end‐point (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.04</p> <p>Adjusted regression coefficient 0.34 −0.22 to 0.90); P = 0.90</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>: the trial authors reported that 110 particpants completed the trial, but did not report the number of participants for each treatment group. </p> </div> </div> <p>Three trials reported changes in viral load, with no statistically significant differences at four to eight weeks (3 trials, 495 participants, data not pooled, see <a href="#CD003650-tbl-0018">Table 13</a>). </p> <div class="table" id="CD003650-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Change in viral load (log10 copies/mL) : Vitamin A versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.1</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>: the trial authors reported that 110 particpants completed the trial, but do not report the number of participants for each treatment group. </p> </div> </div> </section> <section id="CD003650-sec-0094"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>Three trials reported changes in blood retinol concentrations (data not pooled, see <a href="#CD003650-tbl-0019">Table 14</a>). In the only trial with a significant proportion of participants with vitamin A deficiency at baseline (59% &lt; 1.05 µmol/L), median serum concentrations were higher after six weeks of supplementation compared to placebo (P = 0.03) (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>). In the other two trials, in which most participants were not deficient, average blood retinol concentrations remained unchanged after follow‐up periods of four and eight weeks, respectively (<a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>; <a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>). </p> <div class="table" id="CD003650-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Change in nutritional status parameters: vitamin A versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical Measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A (µmol/L)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.03. "No effect" reported for those who were severely deficient at baseline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A (µmol/L)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presented in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presented in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not different"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A (µmol/L)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No change"</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>: Data converted from µg/dL to µmol/L.<br/> <sup>3</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. </p> </div> </div> <p>Note: one further trial from the USA evaluated supplementation with a vitamin A precursor, β‐carotene (60 mg) three times daily (<a href="./references#CD003650-bbs2-0010" title="CoodleyGO , CoodleyMK , LuskR , GreenTR , BakkeAC , WilsonD , et al. Beta‐carotene in HIV infection: an extended evaluation. AIDS1996;10(9):967‐73. ">Coodley 1996 USA</a>). This trial reported an increase in blood concentrations of β‐carotene at three months but no statistically significant effects on CD4+ cell count. </p> </section> <section id="CD003650-sec-0095"> <h5 class="title">Adverse events associated with supplementation</h5> <p>Signs or symptoms of toxicity (headache, nausea, vomiting, diarrhoea, fever) were similar in the intervention and control groups at 24 hours and one week after administration in one trial (<a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a>). No adverse events were reported in the other two trials of vitamin A supplementation (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>; <a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>). Slight skin discolouration was reported by the participants in the intervention group of a one small trial of β‐carotene supplementation (<a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a>). </p> </section> <section id="CD003650-sec-0096"> <h5 class="title">Certainty of the evidence</h5> <p>For a critical appraisal of the summary of evidence, see 'Summary of findings' table 2 (<a href="./full#CD003650-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD003650-sec-0097"> <h4 class="title">Comparison 4: Vitamin D versus placebo</h4> <p>Five trials compared a vitamin D supplement, with or without a calcium supplement, to placebo (see <a href="#CD003650-tbl-0020">Table 15</a>). Participants in two trials received a total of three or four doses of vitamin D (100,000 IU), given every three to five months (<a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>; <a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>). Two trials from the USA used a daily supplement containing 7000 IU vitamin D or 4000 IU vitamin D plus calcium (1000 mg), respectively, for 12 months (<a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>; <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>). A fifth trial from Denmark combined a single dose of vitamin D (100,000 IU) at study entry with a daily vitamin D supplement (1200 IU) plus calcium (1200 mg) for 16 weeks (<a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>). </p> <div class="table" id="CD003650-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Characteristics of trials evaluating Vitamin D supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood 25(OH)<sub>2</sub> vitamin D concentration (ng/mL)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2 (11.5)</p> <p>29.2 (12.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (268)</p> <p>463 (197)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,000 IU then 1200 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose at baseline then daily for 16 weeks (plus 1200 mg calcium daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive; ≤ 30 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (median)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>663 (median)</p> <p>673 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose at baseline and at 3, 6, and 9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive men and women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 (median)</p> <p>25.1 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>346 (median)</p> <p>337 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily for 48 weeks (plus 100 mg calcium)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive; ≤ 25 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 (8.4)</p> <p>17.7 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.17 (0.96)<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily for 12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guinea‐Bissau</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for HIV‐positive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for HIV‐positive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose at baseline, 5, 8 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; IU: International units; TB: Tuberculosis</p> <p><sup>1</sup>Reference value for vitamin D sufficiency: 25 (OH) vitamin D ≥ 30 ng/mL.<br/> <sup>2</sup>RDA for a male aged 19 to 70 years ranges between 5 to 15 µg (200 to 600 IU) daily.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>: only participants with low blood vitamin D concentrations were included in the trial (25(OH)D &lt; 30 ng/mL).<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>: all trial participants were intiated on ART at baseline.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>: 62% of partcipants had a CD4 cell count &gt; 500 cells/mm<sup>3</sup>.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>: 44% of trial participants presented with a detectable viral load at baseline (vitamin D group:13, placebo group: 11). </p> </div> </div> <p>In one trial from Guinnea‐Bissau participants did not receive ART and were on treatment for active pulmonary tuberculosis (<a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>). In the other trials most participants were on ART (see <a href="#CD003650-tbl-0020">Table 15</a>). </p> <p>We considered only one of the five trials to be at low risk of selection bias (<a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>), but three trials adequately described blinding and we considered them to be at low risk of detection and performance bias (<a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>; <a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>; <a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>). </p> <section id="CD003650-sec-0098"> <h5 class="title">Mortality, morbidity, and clinical disease progression</h5> <p>Only a single trial reported mortality in people with active tuberculosis, which was significantly underpowered to evaluate mortality (RR 1.15, 95% CI 0.65 to 2.02; 1 trial, 131 participants, <a href="./references#CD003650-fig-0014" title="">Analysis 3.1</a>). The effect estimate has wide CIs which include both important effects and no effect. </p> </section> <section id="CD003650-sec-0099"> <h5 class="title">Immunological and virological outcomes</h5> <p>Four trials reported changes in the mean or median CD4+ cell counts, over periods from four to 12 months and found no statistically significant effects (4 trials, 288 participants, data not pooled; see <a href="#CD003650-tbl-0021">Table 16</a>). </p> <div class="table" id="CD003650-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): vitamin D versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (268)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 (197)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No changes" in naïve or activated CD4+ cell counts</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 58.1 (−114.5 to 230.7)<sup>2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>346</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>551<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>526<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −22 (P = 0.17)<sup>4</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>: the trial authors also reported no difference in CD4+ cell count at 3, 6, and 9 months.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>: the trial authors reported an increase in CD4+ cell count within both treatment groups (P &gt; 0.001).<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>: subset of 41 HIV‐positive participants who had CD4+ cell counts at baseline and endpoint. </p> </div> </div> <p>One very small study from the USA reported a reduction in viral load over time in those participants with a detectable viral load, using a multi‐level regression model (1 trial, 28 participants, P &lt; 0.05) (<a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>). </p> </section> <section id="CD003650-sec-0100"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>Four trials reported changes in serum concentrations of 25‐hydroxy vitamin D for periods that ranged from four to 12 months. Both single dose supplements and daily supplements resulted in a significant increase in mean or median blood concentrations (ng/mL) (4 trials, 305 participants, data not pooled; see <a href="#CD003650-tbl-0022">Table 17</a>). </p> <div class="table" id="CD003650-tbl-0022"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Change in nutritional status parameters: vitamin D versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical Measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint<br/> (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2 (11.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.6 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (12.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2 (13.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 12.5 (5.9 to 19) P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.3 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (13.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 (6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for end‐point data.<br/> <sup>2</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. </p> </div> </div> <p>Note: one further trial from the USA compared supplementation with 4000 IU vitamin D to 7000 IU vitamin D daily in participants on ART (<a href="./references#CD003650-bbs2-0011" title="DoughertyKA , SchallJI , ZemelBS , TulucF , HouX , RutsteinRM , et al. Safety and efficacy of high‐dose daily vitamin D3 supplementation in children and young adults infected with human immunodeficiency virus. Journal of the Paediatric Infectious Diseases Society2014;3(4):294‐303. [DOI: 10.1093/jpids/piu012] ">Dougherty 2015 USA</a>). This trial reported an increase in blood concentrations of 25‐hydroxy vitamin D with both doses at three months, but no statistically significant effects on viral load. </p> </section> <section id="CD003650-sec-0101"> <h5 class="title">Adverse events associated with supplementation</h5> <p>One trial reported one case of hypercalcaemia in a trial participant who received a single high dose of vitamin D, followed by daily administration (<a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>). The other four trials of vitamin D supplementation did not report any cases of hypercalcaemia (<a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>; <a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>; <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>; <a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>). </p> </section> <section id="CD003650-sec-0102"> <h5 class="title">Certainty of the evidence</h5> <p>For a critical appraisal of the summary of evidence, see 'Summary of findings' table 3 (<a href="./full#CD003650-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> <section id="CD003650-sec-0103"> <h4 class="title">Comparison 5: Zinc versus placebo</h4> <p>Six trials compared a zinc supplement to placebo, given for between two weeks and 18 months (see <a href="#CD003650-tbl-0023">Table 18</a>). Two trials provided daily supplements at the level of the RDA (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>), with one being a small trial from Thailand in participants with immunological discordance on ART (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>). </p> <div class="table" id="CD003650-tbl-0023"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Characteristics of trials evaluating zinc supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood zinc concentration (µg/L)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (copies/mL or log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% with immunological discordance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (median)</p> <p>76 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (median)</p> <p>162 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62%<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (10)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373 (280)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg (women)</p> <p>15 mg (men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peru</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus persistent diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (median)</p> <p>65 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (median)</p> <p>55 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singapore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.9 (15.0)</p> <p>92.2 (18.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (62)</p> <p>131 (65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 338 (38 335)</p> <p>28 093 (41 056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nigeria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mg weekly<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406 (median)</p> <p>460 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83 (median)</p> <p>3.90 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ART: Antiretroviral therapy; RDA: Recommended Daily Allowance; TB: Tuberculosis </p> <p><sup>1</sup>Reference value for zinc sufficiency: &gt; 70 µg/L.<br/> <sup>2</sup>RDA for a male aged 18 to 70 years is 11 mg daily.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>: the trial authors stratified participants with or without low blood zinc concentrations and randomized them to receive zinc or placebo.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>: proportion of trial participants who were on ART and had an undetectable viral load at baseline: 30%<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>: the trial authors excluded participants with normal baseline blood zinc levels (≥ 75 µg/L)<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>: the trial authors randomized participants to receive either weekly doses of zinc (90 mg) and vitamin A (5000 IU), zinc (90 mg) and placebo, or a dual placebo. </p> </div> </div> <p>Higher doses of zinc (50 mg to 100 mg) were given to ARV‐naive participants with persistent diarrhoea for 14 days in one trial in Peru (<a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>) and to participants on ART from Singapore for four weeks (<a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>). In another two trials, participants were on treatment for active pulmonary tuberculosis, and received either a high daily dose of zinc (45 mg) or a weekly dose (90 mg) for six to eight months (<a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>). </p> <p>We considered only one of the six trials to be at low risk of selection bias (<a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>), but five trials adequately described blinding and we judged them to be at low risk of performance or detection bias. </p> <section id="CD003650-sec-0104"> <h5 class="title">Mortality</h5> <p>All three trials that reported deaths were substantially underpowered to confidently detect or exclude effects. None of the trials found statistically significant results and the 95% CI for the overall effect was wide, including both important effects and no effect (RR 1.24, 95% CI 0.53 to 2.86; 3 trials, 433 participants, <a href="./references#CD003650-fig-0015" title="">Analysis 4.1</a>). </p> </section> <section id="CD003650-sec-0105"> <h5 class="title">Morbidity and clinical disease progression</h5> <p>One trial from Peru in ART‐naive adults with persistent diarrhoea reported that a high daily dose of zinc (100 mg) had no effect on the persistence of diarrhoea after two weeks (HR 0.91, 95% CI 0.5 to 1.66; 1 trial, 104 participants, <a href="./references#CD003650-fig-0016" title="">Analysis 4.2</a>; <a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>). </p> <p>One trial from the USA reported that daily zinc supplementation at the level of the DRI for 18 months significantly reduced the proportion of participants with diarrhoea over time (odds ratio (OR) 0.4, 95% CI 0.18 to 0.87; 1 trial, 231 participants, <a href="./references#CD003650-fig-0017" title="">Analysis 4.3</a>; <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>). However, the 95% CI was wide and the trial was also underpowered to have confidence in this result. </p> </section> <section id="CD003650-sec-0106"> <h5 class="title">Immunological and virological outcomes</h5> <p>Three trials reported changes in CD4+ cell count over periods from 28 days to six months (3 trials, 192 participants, data not pooled, see <a href="#CD003650-tbl-0024">Table 19</a>) . One trial reported a statistically significant difference in one small subgroup (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>). This subgroup is substantially underpowered and therefore a positive result is not likely to reflect a true result (low PPV) (<a href="./references#CD003650-bbs2-0093" title="ButtonKS , LoannidisJPA , MokryszC , NosekBA , FlintJ , RobinsonES , et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews. Neuroscience2013;14(5):365‐76. ">Button 2013</a>). However, one additional trial from the USA in adults on ART reported a statistically significant reduction in the risk of reaching a CD4+ count less than 200 cells/mm³ after supplementation for 18 months (RR 0.24, 95% CI 0.10 to 0.56; 1 trial, 231 participants; <a href="#CD003650-tbl-0024">Table 19</a>; <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>). </p> <div class="table" id="CD003650-tbl-0024"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Change in CD4 count (cells/mm3) : zinc versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>(IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> <p>(151 to 213)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> <p>(190 to 286)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> <p>(139 to 182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> <p>(162 to 254)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>17</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supplementation increased median CD4+ in those with low zinc at baseline (P = 0.042) but not those with normal zinc (P &gt; 0.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385</p> <p>(285)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361</p> <p>(275)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduced risk of CD4+ &lt; 200 cells/µL<sup>2</sup> with intervention (RR 0.24, 95% CI 0.10 to 0.56) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> <p>(61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> <p>(73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> <p>(63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> <p>(75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> <p>(327 to 485)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>422</p> <p>(331 to 512)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460<br/> (351 to 569) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>403</p> <p>(309 to 569)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not significant"</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: Confidence interval; IQR: Interquartile range; RR: Relative risk; SD: Standard deviation </p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data. </p> </div> </div> <p>Three trials reported changes in viral load over periods from 28 days to 18 months, and all three trials (including <a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>) reported no statistically significant differences with supplementation (3 trials, 400 participants, data not pooled, see <a href="#CD003650-tbl-0025">Table 20</a>). </p> <div class="table" id="CD003650-tbl-0025"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Change in viral load (copies/mL or log10 copies/mL): zinc versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> <p>(1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> <p>(1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not affected by supplementation"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,740</p> <p>(36,856)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,652</p> <p>(39,418)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,286</p> <p>(40,297)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,551</p> <p>(39,013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<br/> (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83 (3.52 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.28 (3.86 to 4.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (3.53 to 4.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (3.67 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not significant"</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: Confidence interval; SD: Standard deviation; TB: Tuberculosis</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data. </p> </div> </div> </section> <section id="CD003650-sec-0107"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>Two trials reported blood zinc concentrations at the trial endpoints of 28 days and 6 months, respectively (two trials, data not pooled, see <a href="#CD003650-tbl-0026">Table 21</a>) (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>; <a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>). No difference in zinc concentrations were reported, except for a small number of participants from one trial in Thailand who were deficient in zinc at baseline (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>). </p> <div class="table" id="CD003650-tbl-0026"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Changes in nutritional status parameters: zinc versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical Measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>(IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> <p>(66 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> <p>(71 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(66 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(69 to 82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"higher after zinc supplementation, particularly in patients with low plasma zinc levels at baseline" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted<sup>4</sup> regression coefficient ß = 0.04; P = 0.0472 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.2 (18.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120.3 (68.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.9 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111.8 (37.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.67</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: IQR: Interquartile range; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>: participants with or without low blood zinc concentrations were stratified and randomized to receive zinc or placebo.<br/> <sup>3</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>: regression coefficient adjusted for C‐reactive protein levels (biomarker for inflammation).<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>: the trial authors reported a smaller proportion of participants in the supplemented group with low zinc levels after 14 days of follow‐up (65.6% versus 93.7%; P = 0.01). </p> </div> </div> <p>In addition, the authors of one trial from Peru in adults with persistent diarrhoea reported a smaller proportion of supplemented participants with low blood zinc levels after 14 days (1 trial, 159 participants, P = 0.01, see <a href="#CD003650-tbl-0026">Table 21</a>) (<a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>). Another trial from the USA reported significantly higher blood zinc concentrations in the supplemented group at the study endpoint of 18 months, adjusted for C‐reactive protein levels (1 trial, 231 participants, ß = 0.04; P = 0.047) (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>). </p> </section> <section id="CD003650-sec-0108"> <h5 class="title">Adverse events associated with supplementation</h5> <p>In one trial one participant in the intervention group developed an erythematous rash after taking a standard dose supplement for one month, which resolved when the supplement was discontinued (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>). Two trials of high dose supplementation reported similar numbers of participants in the intervention and control groups with gastrointestinal symptoms such as vomiting, diarrhoea or abdominal pain (<a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>; <a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>). </p> </section> <section id="CD003650-sec-0109"> <h5 class="title">Certainty of the evidence</h5> <p>For a critical appraisal of the summary of evidence, see 'Summary of findings' table 4 (<a href="./full#CD003650-tbl-0004">summary of findings Table 4</a>). </p> </section> </section> <section id="CD003650-sec-0110"> <h4 class="title">Comparison 6: Selenium versus placebo</h4> <p>Four trials compared a daily selenium supplement (200 µg) to placebo, given for between nine and 24 months (see <a href="#CD003650-tbl-0027">Table 22</a>). Two trials recruited only ART‐naive participants (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>), and two recruited both ART‐naive people and people on ART (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). </p> <div class="table" id="CD003650-tbl-0027"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Characteristics of trials evaluating selenium supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood selenium concentration (µg/l)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (copies/mL or log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botswana</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (10)</p> <p>70 (24)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 500 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive IDUs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy 21%</p> <p>HAART 46%<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427 (421)</p> <p>378 (295)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55,257 (147, 152)</p> <p>60,905 (144, 292)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (264)</p> <p>441 (266)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,558 (87,051)</p> <p>10,491 (20,251)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rwanda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552 (median)</p> <p>527 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (median)</p> <p>3.9 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; HAART: Highly active antiretroviral therapy; IDUs: injection drug users. </p> <p><sup>1</sup>Reference values used to define selenium sufficiency: &gt; 75 µg/L or &gt; 85 µg/L<br/> <sup>2</sup>RDA for a male aged 18 to 70 years is 55 µg daily.<br/> <sup>3</sup>Sales 2010 BWA in <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: Baseline selenium concentrations reported for a sub‐sample of 79 trial participants.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: the trial authors reported fewer ARV naive participants in the selenium group (24%) compared to the placebo group (37%) at baseline.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: participants with low baseline blood selenium levels (≤ 85 µg/L) were excluded from the trial.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>: participants with low baseline blood selenium levels (≤ 75 µg/L) were excluded from the trial.<br/> <sup>7</sup><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>: participants who were eligible for ART were excluded from the trial. </p> </div> </div> <p>Of the four trials, we only judged one to be at low risk of selection bias (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>), and three to be at low risk of performance and detection bias as they adequately described blinding (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>; <a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). </p> <section id="CD003650-sec-0111"> <h5 class="title">Mortality</h5> <p>Not reported.</p> </section> <section id="CD003650-sec-0112"> <h5 class="title">Morbidity and clinical disease progression</h5> <p>One trial in HIV‐positive injection drug users in the USA reported a statistically significant reduction in the risk of hospital admissions for opportunistic infections and HIV‐related conditions after supplementation for 12 months (RR 0.40, 95% CI 0.21 to 0.75; 1 trial, 186 participants, <a href="./references#CD003650-fig-0018" title="">Analysis 5.1</a>). However, the trial authors stated that fewer participants in the placebo group compared to the selenium group were on ART at baseline (P &lt; 0.05) which may have influenced this result (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>). </p> </section> <section id="CD003650-sec-0113"> <h5 class="title">Immunological and virological outcomes</h5> <p>All four trials reported measures of change in CD4+ cell count with mixed findings and poor reporting of baseline and end values (see <a href="#CD003650-tbl-0028">Table 23</a>). In people not taking ART we observed the following. </p> <div class="table" id="CD003650-tbl-0028"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): selenium versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint<br/> (as reported by study authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>(IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423</p> <p>(347 to 539)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411</p> <p>(327 to 545)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427(421)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376(295)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (264)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441 (266)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552 (470 to 636)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527 (465 to 610)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; HR: hazard ratio; IQR: interquartile range; RR: risk ratio; SD: standard deviation<br/> <sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: the trial authors reported no reduction in risk of CD4+ falling to &lt; 250 cells/µL<sup>2</sup> (HR 0.83, 95% CI 0.48 to 1.42).<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: the trial authors reported that 46% of participants in the placebo group versus 25% in the selenium group experienced a decline in CD4 cell count &gt; 50 cells/mm<sup>3</sup> (P = 0.01).<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>: the trial authors reported in a multiple regression model that increased selenium levels predicted a greater decrease in viral load (P &lt; 0.02), which predicted a greater increase in CD4 counts (P &lt; 0.04).<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>: the trial authors reported a 44 % reduction in the rate of CD4+ cell decline per month (MD 1.74, 95% CI 0.31 to 3.17). No reduction in risk of CD4+ falling to &lt; 350 cells/µL<sup>2</sup> (RR 0.81, 95% CI 0.61 to 1.09). </p> </div> </div> <p> <ul id="CD003650-list-0011"> <li> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> reported no significant reduction in the risk of reaching a CD4+ count &lt; 250 cells/mm³ with selenium supplements for two years in people not on ART (HR 0.83 95% CI: 0.48 to 1.42; 1 trial, 437 participants), and <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> reported no significant reduction in the risk of reaching a CD4+ count of less than 350 cells/mm³ (RR 0.81 95% CI 0.61 to 1.09; 1 trial, 300 participants) </p> </li> <li> <p>However, <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> reported a reduction in the monthly rate of CD4 cell depletion (MD 1.74, 95% CI 0.31 to 3.17; 1 trial, 300 participants) </p> </li> </ul> </p> <p>In populations with mixed exposure to ART, we observed the following.</p> <p> <ul id="CD003650-list-0012"> <li> <p><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a> reported that fewer trial participants in the supplemented group experienced a CD4 cell decline of greater than 50 cells/mm³ (P = 0.01; authors' own figures) </p> </li> <li> <p><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a> reported a multiple regression model that found higher selenium levels predicted a greater increase in CD4+ cell counts at 9 months (P &lt; 0.04; authors' own figures). However, this trial is at high risk of selective reporting as the statistically significant results are only for a subgroup of participants classified as 'selenium responders'. It is unclear if this classification or analysis was planned a priori </p> </li> </ul> </p> <p>Only three trials reported effects on viral load and statistically significant benefits were only reported from the multiple regression model used by <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>. </p> </section> <section id="CD003650-sec-0114"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>Three trials reported statistically significant increases in blood selenium concentrations of participants after supplementation for 6 to 12 months (527 participants, data not pooled, see <a href="#CD003650-tbl-0029">Table 24</a>) </p> <div class="table" id="CD003650-tbl-0029"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Change in nutritional status parameters: selenium versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported <sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 31.7 (27.4 to 36); P&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sales 2010<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 (15.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (12.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P&lt;0.001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: the trial authors reported proportions of participants with blood selenium levels &lt; 135 µg/L at the end of the trial: 89% versus 47% (P = 0.001).<br/> <sup>4</sup>Sales 2010: data reported on a subsample of trial participants from the trial by <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>. </p> </div> </div> </section> <section id="CD003650-sec-0115"> <h5 class="title">Adverse events associated with supplementation</h5> <p>One trial reported no differences in symptoms such as nausea, vomiting and skin and hair changes of participants, but those in the intervention group were more likely to report anxiety (P = 0.04) and sleep symptoms (P = 0.01). (<a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>). Another trial stated that all serious adverse events reported (which included acute diarrhoea, vomiting, or severely elevated ALT levels) were adjudicated as having a remote relationship to the intervention (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>). Two other selenium supplementation trials reported no adverse events (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). </p> </section> <section id="CD003650-sec-0116"> <h5 class="title">Certainty of the evidence</h5> <p>For a critical appraisal of the summary of evidence, see 'Summary of findings' table 5 (<a href="./full#CD003650-tbl-0005">summary of findings Table 5</a>). </p> </section> </section> <section id="CD003650-sec-0117"> <h4 class="title">Comparison 7: Vitamin E plus vitamin C versus placebo</h4> <p>One small Canadian trial compared high daily doses of vitamins E (800 IU) and C (1000 mg) to placebo in adults on combination ART for three months. Participants were followed up for six months because of a possible carry‐over effect of the intervention (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>). </p> <p>Allocation concealment was not well described and so the risk of selection bias was unclear, but the trial was adequately blinded. </p> <section id="CD003650-sec-0118"> <h5 class="title">Mortality</h5> <p>Not reported.</p> </section> <section id="CD003650-sec-0119"> <h5 class="title">Morbidity and clinical disease progression</h5> <p><a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a> reported that high daily doses of vitamin E and C for three months had no effect on the risk of new AIDS defining infections after six months (RR 3.54, 95% CI 0.43 to 29.43; 1 trial, 49 participants). </p> </section> <section id="CD003650-sec-0120"> <h5 class="title">Immunological and virological outcomes</h5> <p><a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a> reported no effect on viral load (log<sub>10</sub>copies/mL) after three months supplementation of high daily doses of vitamin E and C (MD 0.95 log <sub>10</sub> copies/mL, 95% CI 0.14 to 2.04; 1 trial, 49 participants). </p> </section> <section id="CD003650-sec-0121"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>This trial reported that high daily doses of vitamins E and C for three months increased blood concentrations of vitamin E (µmol/L) (MD 28.70, 95% CI 20.01 to 37.39; one trial, 49 participants) and vitamin C (µmol/L) (MD 27.30, 95% CI 12.88 to 41.72; 1 trial, 49 participants) of adults on ART (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>). </p> </section> <section id="CD003650-sec-0122"> <h5 class="title">Adverse events associated with supplementation</h5> <p>Two participants in the intervention group reported epigastric discomfort (<a href="./references#CD003650-bbs2-0001" title="AllardJP , AghdassiE , ChauJ , TamC , KovacsCM , SalitIE , et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV‐infected subjects. AIDS1998;12(13):1653‐9. ">Allard 1998 CAN</a>). </p> </section> </section> <section id="CD003650-sec-0123"> <h4 class="title">Comparison 8: Folinic acid versus placebo</h4> <p>One small Brazilian trial compared the effect of a daily folinic acid supplement (5 mg) to placebo on the vascular response of 30 HIV‐positive adults on ART (<a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>). This trial was at low risk of selection bias, and detection and performance bias. </p> <section id="CD003650-sec-0124"> <h5 class="title">Mortality</h5> <p>Not reported.</p> </section> <section id="CD003650-sec-0125"> <h5 class="title">Morbidity and clinical disease progression</h5> <p>Not reported.</p> </section> <section id="CD003650-sec-0126"> <h5 class="title">Immunological and virological outcomes</h5> <p>This trial reported no difference in median CD4 cell counts after daily supplementation of folinic acid for four weeks (1 trial, 30 participants, P = 0.994) (<a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>). </p> </section> <section id="CD003650-sec-0127"> <h5 class="title">Nutritional status and blood micronutrient concentrations</h5> <p>This trial reported increases in blood concentrations of folate and vitamin B12 after supplementation of folinic acid for four weeks (1 trial, 30 participants, P &lt; 0.001) (<a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>). </p> </section> <section id="CD003650-sec-0128"> <h5 class="title">Adverse events associated with supplementation</h5> <p>No adverse events were reported (<a href="./references#CD003650-bbs2-0014" title="GrigolettiSS , GuindaniG , MoraesRS , RibeiroJP , SprinzE . Short‐term folinic acid supplementation improves vascular reactivity in HIV‐infected individuals: a randomized trial. Nutrition2013;29(6):886‐91. ">Grigoletti 2013 BRA</a>). </p> </section> </section> <section id="CD003650-sec-0129"> <h4 class="title">Comparison 9: Iron versus no iron</h4> <p>One trial in the USA compared the effect of a daily micronutrient supplement containing iron to a supplement without iron in female injection drug users for 12 months. Of the trial participants who were HIV‐positive, approximately one‐third were on HAART at baseline and during the study (<a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>). </p> <section id="CD003650-sec-0130"> <h5 class="title">Mortality</h5> <p>Not reported.</p> </section> <section id="CD003650-sec-0131"> <h5 class="title">Morbidity and clinical disease progression</h5> <p>Not reported.</p> </section> <section id="CD003650-sec-0132"> <h5 class="title">Immunological and virological outcomes</h5> <p>This trial reported no difference in CD4 cell counts or viral load measurements in participants who received the micronutrient plus iron supplement compared to those who received the supplement without iron for 12 months (CD4 cell count (cells/mm³): MD 35, 95% CI −83.5 to 153.5; viral load (log<sub>10</sub>copies/mL): MD −0.4, 95% CI −0.99 to 0.19; 1 trial, 103 participants; <a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>). </p> </section> <section id="CD003650-sec-0133"> <h5 class="title">Adverse events associated with supplementation</h5> <p>No adverse events were reported (<a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003650-sec-0134" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003650-sec-0134"></div> <section id="CD003650-sec-0135"> <h3 class="title" id="CD003650-sec-0135">Summary of main results</h3> <section id="CD003650-sec-0136"> <h4 class="title">Multiple micronutrients</h4> <p>Routine multiple micronutrient supplementation may have little or no effect on mortality in adults living with HIV, but the pooled analysis remains underpowered to confidently exclude small effects (<i>low certainty evidence</i> ). Trials were conducted in antiretroviral therapy (ART)‐naïve adults (3 trials, 1068 participants, <i>low certainty evidence</i> ), adults on ART (1 trial, 400 participants, <i>very low certainty evidence</i> ), and adults with concurrent active tuberculosis (3 trials, 1429 participants, <i>low certainty evidence</i>). </p> <p>Routine supplementation for up to two years, has also not been shown to have consistent benefits on either mean CD4+ cell count (<i>low certainty evidence</i> ) or mean viral load (<i>moderate certainty evidence</i>). One recent trial in ART‐naïve adults reported a reduction in the risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation in Botswana. However, this effect was only robust in the trial arm receiving multiple micronutrients plus selenium (not either supplementation alone) and is inconsistent with the findings of other trials using similar combinations of micronutrients and selenium. </p> <p>In one additional trial that compared high dose multiple micronutrient supplementation with standard doses in people on antiretroviral therapy (ART), peripheral neuropathy was reduced with high dose supplements compared to standard dose, but the trial was stopped early due to increased adverse events in the high dose group. </p> </section> <section id="CD003650-sec-0137"> <h4 class="title">Single or dual micronutrients</h4> <p>None of the trials of single or dual micronutrient supplements were adequately powered to assess for effects on mortality or morbidity outcomes such as hospital admissions and persistence or rate of diarrhoea. Clinically important effects on CD4+ cell count or viral load were not reported. Supplementation probably does increase blood concentrations of vitamin D and zinc, and may also increase blood concentrations of vitamin A, especially in those who are deficient at baseline. </p> </section> </section> <section id="CD003650-sec-0138"> <h3 class="title" id="CD003650-sec-0138">Overall completeness and applicability of evidence</h3> <p>The included trials of multiple micronutrient supplements were predominantly conducted in people who either were not taking ART or were on concurrent treatment for tuberculosis. In these populations, routine supplementation has not been shown to consistently improve disease progression as measured by average CD4+ cell count. One recent well‐conducted trial, from Botswana detected a benefit in the group receiving multivitamins with selenium but not with multivitamins alone. However, the lack of demonstrable benefit in other trials with similar selenium content, suggest that this effect should be repeated before reliable conclusions can be drawn. </p> <p>The trials of single or dual micronutrient supplements included more participants on ART, and several were conducted in populations with proven micronutrient deficiencies. Despite this the only demonstrable benefits were improvements in serum levels of some micronutrients. However, these effects may be enough for some to recommend routine supplementation in similar populations. </p> <p>There are several possible explanations for the lack of benefit seen in many of these trials. </p> <p> <ul id="CD003650-list-0013"> <li> <p>The period of supplementation may have been insufficient to demonstrate effects, with benefits only accruing over prolonged periods of supplementation. Supplementation ranged from as little as four weeks up to two years. </p> </li> <li> <p>The prevalence of micronutrient deficiencies may have been too low in some of these populations to demonstrate an effect. Baseline micronutrient status was poorly assessed in many of the included trials, particularly those evaluating multiple micronutrients, so it is difficult to determine which populations these negative results should be applied to. Only one trial reported adjustment of their analysis of blood micronutrient concentrations for the effect of inflammation, an important confounder. </p> </li> <li> <p>The doses supplemented varied considerably. Many trials evaluated doses significantly higher than the daily recommended intake, and one trial of multiple micronutrients directly compared high doses with standard doses to investigate this. However, it should be noted that the high doses were not well‐tolerated in this trial. </p> </li> <li> <p>The trials may simply be too small to demonstrate effects. Certainly there is insufficient evidence to say that micronutrients could never have effects. </p> </li> </ul> </p> <p>Given the lack of benefit in those not on ART, it seems unlikely that large effects would be seen in those who are taking ART, but adequately powered trials may still be justifiable to explore this. There may be a number of ways by which specific micronutrients may impact on or interact with ART, including aspects of drug pharmacokinetics. However, the clinical significance of these interactions remains to be determined (<a href="./references#CD003650-bbs2-0109" title="RaitenDJ . Nutrition and pharmacology: general principles and implications for HIV. American Journal of Clinical Nutrition2011;94(6):1697S‐702S. ">Raiten 2011</a>). </p> </section> <section id="CD003650-sec-0139"> <h3 class="title" id="CD003650-sec-0139">Quality of the evidence</h3> <p>We considered the certainty of the evidence for most of the outcomes in this review to be low or very low, meaning that we can have only minimal confidence in these effects. We downgraded the certainty of the evidence mainly for the following reasons. </p> <p> <ul id="CD003650-list-0014"> <li> <p>Indirectness: since micronutrient deficiencies differ widely among populations it is difficult to generalize the findings of a single trial, or even a few trials, to all settings, and all populations. </p> </li> <li> <p>Imprecision: most included trials were small and well below the optimal information size for the outcomes that were being measured and therefore not able to reliably detect or exclude an effect. </p> </li> </ul> </p> </section> <section id="CD003650-sec-0140"> <h3 class="title" id="CD003650-sec-0140">Potential biases in the review process</h3> <p>We tried to minimize any biases in the review process by performing a comprehensive search of the literature, and by independently selecting studies, appraising studies, and extracting data. Two review authors, MV and SD, assessed the risk of bias of the new included studies using the updated 'Risk of bias' tool (<a href="./references#CD003650-bbs2-0102" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Version 5.1.0. The Cochrane Collaboration. ">Higgins 2011</a>). </p> <p>This review included outcome data for HIV participants from four RCTs that included both HIV‐positive and HIV‐negative participants without stratified randomization (<a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>; <a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>). </p> </section> <section id="CD003650-sec-0141"> <h3 class="title" id="CD003650-sec-0141">Agreements and disagreements with other studies or reviews</h3> <p>In the previous version of this Cochrane Review, <a href="./references#CD003650-bbs2-0126" title="IrlamJ , VisserMME , RollinsNN , SiegfriedN . Micronutrient supplementation in children and adults with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD003650.pub3] ">Irlam 2010</a> concluded that further trials of single supplements (vitamin D, zinc, and selenium) were required to build the evidence base for adults and that the long‐term clinical benefits, adverse effects, and optimal formulation of multiple micronutrient supplements required further investigation. </p> <p><a href="./references#CD003650-bbs2-0097" title="ForresterJE , SztamKA . Micronutrients in HIV/AIDS: is there evidence to change the WHO 2003 recommendations?. American Journal of Clinical Nutrition2011;94(6):1683S‐9S. ">Forrester 2011</a> conducted a narrative review to investigate whether the 2003 WHO recommendations for micronutrient intake in HIV‐positive adults should change. This review focused primarily on the results of nine trials of multiple micronutrient supplementation; seven trials in non‐pregnant HIV‐positive adults, and two in pregnant HIV‐positive women. The authors noted that "five of the six trials that used high‐dose multiple micronutrients showed benefits in terms of either improved CD4 cell counts or survival", but also that "many of these trials were small and of short duration, and the long‐term risks and benefits of high‐dose multiple micronutrients are not established". Our analysis and appraisal of the evidence agrees that there is currently insufficient evidence to make firm conclusions about the effects of supplementation. </p> <p>For the effects of micronutrient supplementation in pregnant women and children with HIV, see the separate Cochrane reviews by <a href="./references#CD003650-bbs2-0116" title="SiegfriedN , IrlamJH , VisserME , RollinsNN . Micronutrient supplementation in pregnant women with HIV infection. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD009755] ">Siegfried 2012</a> and <a href="./references#CD003650-bbs2-0104" title="IrlamJH , SiegfriedN , VisserME , RollinsNC . Micronutrient supplementation for children with HIV infection. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010666] ">Irlam 2013</a>. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003650-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD003650-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD003650-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD003650-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multiple micronutrients versus placebo, Outcome 1 Mortality." data-id="CD003650-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Multiple micronutrients versus placebo, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multiple micronutrients versus placebo, Outcome 2 Hospital admissions." data-id="CD003650-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Multiple micronutrients versus placebo, Outcome 2 Hospital admissions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multiple micronutrients versus placebo, Outcome 3 Clinical disease progression." data-id="CD003650-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Multiple micronutrients versus placebo, Outcome 3 Clinical disease progression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multiple micronutrients versus placebo, Outcome 4 CD4+ cell count." data-id="CD003650-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Multiple micronutrients versus placebo, Outcome 4 CD4+ cell count.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multiple micronutrients versus placebo, Outcome 5 CD4+ cell count at longest follow‐up; subgrouped by participant characteristics." data-id="CD003650-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Multiple micronutrients versus placebo, Outcome 5 CD4+ cell count at longest follow‐up; subgrouped by participant characteristics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multiple micronutrients versus placebo, Outcome 6 Viral load." data-id="CD003650-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Multiple micronutrients versus placebo, Outcome 6 Viral load.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multiple micronutrients versus placebo, Outcome 7 Viral load at longest follow‐up; sub‐grouped by participant characteristics." data-id="CD003650-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Multiple micronutrients versus placebo, Outcome 7 Viral load at longest follow‐up; sub‐grouped by participant characteristics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High dose multivitamins versus standard dose, Outcome 1 Mortality." data-id="CD003650-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 High dose multivitamins versus standard dose, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High dose multivitamins versus standard dose, Outcome 2 CD4+ cell count." data-id="CD003650-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 High dose multivitamins versus standard dose, Outcome 2 CD4+ cell count.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High dose multivitamins versus standard dose, Outcome 3 Viral load." data-id="CD003650-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 High dose multivitamins versus standard dose, Outcome 3 Viral load.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vitamin D versus placebo, Outcome 1 Mortality." data-id="CD003650-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus placebo, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zinc versus placebo, Outcome 1 Mortality." data-id="CD003650-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Zinc versus placebo, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zinc versus placebo, Outcome 2 Persistence of diarrhoea." data-id="CD003650-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Zinc versus placebo, Outcome 2 Persistence of diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zinc versus placebo, Outcome 3 Rate of diarrhoea." data-id="CD003650-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Zinc versus placebo, Outcome 3 Rate of diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003650-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/urn:x-wiley:14651858:media:CD003650:CD003650-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_t/tCD003650-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Selenium versus placebo, Outcome 1 Hospital admissions." data-id="CD003650-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Selenium versus placebo, Outcome 1 Hospital admissions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/media/CDSR/CD003650/image_n/nCD003650-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003650-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection (with and without concurrent tuberculosis, with and without ART)<br/> <b>Settings:</b> all settings<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard or high dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 8 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (72 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.72 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2897<br/> (7 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on mortality</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>Follow‐up: 11 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> <p>(85 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> </p> <p>(0.61 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>881</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on hospital admissions</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 6 weeks to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>147 to 483 cells/mm</b>³ </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient group was</p> <p><b>26.40 cells/mm</b> ³ <b>higher</b> </p> <p>(22.91 lower to 75.70 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1581<br/> (6 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3,6</sup> </p> <p>due to indirectness and inconsistency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> <p>Follow‐up: 6 weeks to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>4.1 to 5.4 log<sub>10</sub>copies/mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.10 log<sub>10</sub>copies/mL lower</b> </p> <p>(0.26 lower to 0.06 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>840</p> <p>(4 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients probably have little or no effect on viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nutritional status</b> </p> <p>Follow‐up: 4 weeks to 1.9 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1007<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,8,9</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on nutritional status parameters</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; BMI: body mass index; CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: most trials were at low risk of selection bias and used placebos to prevent performance or detection bias.<br/> <sup>2</sup>No serious heterogeneity: none of the trials found statistically significant effects overall (although one small subgroup from one trial in Tanzania did find a statistically significant difference this is probably a chance finding).<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: although most trials reported this outcome, only one of these (from Uganda using standard dose micronutrients) included a substantial number of adults on ART in line with current recommendations. The other trials used standard or high dose micronutrients and were conducted in ART‐naive adults (in Botswana, Zambia, and Thailand), and adults with concurrent tuberculosis (in Tanzania and Malawi).<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important effects and no effect. The overall meta‐analysis remains underpowered to confidently exclude effects.<br/> <sup>5</sup>Downgraded by 2 for very serious indirectness: these two trials were conducted in Thailand (high dose micronutrients in ART‐naive adults) and Uganda (standard dose micronutrients in adults on ART). The finding of no effect may not apply to all populations and settings.<br/> <sup>6</sup>Downgraded by 1 for serious inconsistency: in total eight trials reported a measure of CD4+ cell count although we could only include six trials in this meta‐analysis. Of note, one recent trial in Botswana among ART‐naive adults (not included in the meta‐analysis) reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation. This finding is inconsistent with other trials that used similar combinations of micronutrients and selenium.<br/> <sup>7</sup>Downgraded by 1 for serious indirectness: in total four trials in ART‐naive adults, with concurrent TB (in Tanzania and Malawi) or without TB (in Kenia and Thailand), reported viral load. The finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>8</sup>Downgraded by 2 for serious indirectness: only three trials (from Uganda, Zambia, and Tanzania) reported measures of nutritional status (BMI, weight, mid‐upper arm circumference (MUAC), lean body mass). The finding of no effect may not apply to all populations and settings.<br/> <sup>9</sup>Downgraded by 1 for serious imprecision: we were unable to pool data but the 95% CIs of the individual trials were wide and included clinically important effects and no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003650-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin A compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin A compared to placebo for adults with HIV infection currently taking ART or not</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> any<br/> <b>Intervention:</b> vitamin A (single dose or daily dose)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count (cells/mm</b> ³<b>)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A may have little or no short‐term effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load (log<sub>10</sub>copies/mL)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>495<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A may have little or no short‐term effect on viral load</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in vitamin A concentrations (µmol/L)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>495</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,4,5</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A may increase blood concentrations of persons with HIV with low baseline concentrations </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for serious risk of bias: one trial in Kenya with 400 participants reported high attrition overall (11.5%) and the trial authors stated that participants who were lost to follow‐up had more advanced HIV disease and were more likely to be vitamin A deficient (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>).<br/> <sup>2</sup>No serious heterogeneity: none of the trials found statistically significant effects.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: trials were conducted in the USA and Kenya, and most participants were not on antiretroviral therapy (ART). This may not completely exclude the possibility of effects in some settings or populations.<br/> <sup>4</sup>No serious imprecision: no statistically significant differences were seen. Although two trials were underpowered, one trial in Kenya with 400 participants was adequately powered to reliably detect a clinically beneficial effect on CD4 cell count, viral load, and blood vitamin A concentrations (<a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>).<br/> <sup>5</sup>No serious heterogeneity: a statistical significant increase in blood vitamin concentrations was reported in one trial from Kenya with 400 participants. Baseline blood vitamin concentrations of these participants were much lower than the 95 participants in the other two trials in the USA. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin A compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003650-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vitamin D compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin D compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> any<br/> <b>Intervention:</b> vitamin D (repeated single doses or daily dose with or without additional calcium)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vitamin D</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> </p> <p>(165 to 513)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> </p> <p>(0.65 to 2.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if vitamin D supplements have any effect on mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count (cells/mm</b> ³<b>)</b> <br/> Follow‐up: 16 weeks to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> <p>due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D supplements may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load (log<sub>10</sub>copies/mL)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo group was</p> <p><b>3.78</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.66 lower</b> </p> <p>(1.37 lower to 0.05 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 participants</p> <p>(1 trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5,6</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if vitamin D supplements have an effect on viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in 25(OH) vitamin D concentrations (ng/mL)</b> <br/> Follow‐up: 16 weeks to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7,8</sup> </p> <p>due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D supplements probably increase blood 25(OH) vitamin D levels</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: the included trials were generally at low risk of bias.<br/> <sup>2</sup>Downgraded by 2 for serious indirectness: only a single trial from Guinea‐Bissau reports the number of deaths after 12 months follow‐up in HIV‐positive participants on treatment for active tuberculosis (<a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>).<br/> <sup>3</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both a relative risk reduction and relative risk increase of greater than 25%.<br/> <sup>4</sup>Downgraded by 2 for serious indirectness: no changes in mean or median CD4 cell counts were reported from these four small trials from Italy (<a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>), the USA (<a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>), Guinea‐Bissau (<a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>), or Denmark (<a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a>). This doesn't exclude the possibility of effects in some populations.<br/> <sup>5</sup>Downgraded by 2 for very serious indirectness: this is a single very small trial from the USA.<br/> <sup>6</sup>Downgraded by 1 for serious imprecision: the trial is very small, and the 95% CI is wide and includes no effect.<br/> <sup>7</sup>No serious heterogeneity: all four studies report a statistical significant increase in blood 25(OH) vitamin D concentrations (ng/mL).<br/> <sup>8</sup>Downgrade by 1 for serious risk of indirectness: all studies were conducted in high income countries (Italy, Canada, Denmark, and the USA). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vitamin D compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003650-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Zinc compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> any<br/> <b>Intervention:</b> zinc (daily or weekly dose)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Zinc</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 6 to 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> <p>(58 to 315)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> <br/> (0.53 to 2.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if zinc supplements have any effect on mortality</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of diarrhoea</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.18 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if zinc supplements have any effect on the frequency of diarrhoea</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in CD4 cell count (cells/mm</b> ³<b>)</b> </p> <p>Follow‐up: 1 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>431<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,6</sup> </p> <p>due to indirectness and inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc supplements may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in viral load (log<sub>10</sub>copies/mL)</b> </p> <p>Follow‐up: 1 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,7</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc supplements may have little or no effect on viral load</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in blood zinc concentrations</b> </p> <p>Follow‐up: 1 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc supplements probably increase blood zinc concentrations of persons with HIV with low baseline concentrations </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; RR: risk ratio; OR: odds ratio; HR: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: the included studies were generally at low risk of bias.<br/> <sup>2</sup>Downgraded by 1 for serious indirectness: the available data is from limited settings and populations. The findings are not easily generalized to other populations.<br/> <sup>3</sup>Downgraded by 2 for serious imprecision: the 95% CI around the absolute effect is very wide and crosses 1. The overall meta‐analysis is underpowered to confidently exclude effects.<br/> <sup>4</sup>Downgraded by 2 for very serious indirectness: this finding is from a single study in the USA and may not be applicable to other settings.<br/> <sup>5</sup>Downgraded by 1 for serious imprecision: although the 95% CI does not cross the line of no effect this trial is underpowered to detect or exclude clinically important differences.<br/> <sup>6</sup>Downgrade by 1 for serious inconsistency: one very small trial from Singapore reports a marginal improvement in median CD4 count after 6 months of standard dose supplements (<a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>), and one study reports a significant reduction in the risk of decline of CD4+ to &lt; 200 in those taking standard supplements (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>). Two other small studies using high dose supplements report no statistically significant difference (<a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>).<br/> <sup>7</sup>Downgraded by 1 for serious imprecision: all three trials were underpowered to include or exclude clinically important effects (<a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>; <a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>; <a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>).<br/> <sup>8</sup>No serious inconsistency: three trials report an increase in blood zinc concentrations over time. The participants in one trial that did not report an increase in blood concentrations after supplementation, were not deficient in zinc at baseline (<a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Zinc compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003650-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Selenium compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Selenium compared to placebo for adults with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection<br/> <b>Settings:</b> all settings<br/> <b>Intervention:</b> selenium (daily dose)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Selenium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> <br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> <br/> (65 to 232) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.4</b> <br/> (0.21 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to risk of bias, indirectness, and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if selenium supplements reduce hospital admissions</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in CD4 cell count (cells/mm</b> ³<b>)</b> </p> <p>Follow‐up: 9 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1187 participants<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium supplements may have little or no effect on CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in viral load (log<sub>10</sub>copies/mL)</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439 participants<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium supplements may have little or no effect on viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in selenium concentrations (µg/L)</b> <br/> Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium supplements may increase blood selenium concentrations</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; CI: confidence interval; RR: risk ratio; HR: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for serious risk of bias: high attrition due to participants with incomplete medical records. In addition, fewer participants in the placebo group compared to the selenium group were on antiretroviral therapy (ART) at baseline (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>).<br/> <sup>2</sup>Downgraded by 1 for serious indirectness: only a single trial is available from the USA in HIV‐positive intravenous drugs users. This is not easily generalized to other HIV‐positive populations.<br/> <sup>3</sup>Downgraded by 1 for serious imprecision: this trial is underpowered to detect clinically important differences.<br/> <sup>4</sup>Downgraded by 1 for serious risk of bias: two of the three trials reported high attrition rates (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). In one trial fewer participants in the placebo group compared to the selenium group were on ART at baseline (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>).<br/> <sup>5</sup>Downgraded by 1 for serious imprecision: three of the four trials were underpowered to include or exclude clinically important effects (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>; <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>). One trial from Botswana was adequately powered and reported no effect on the decline in CD4 cell counts of ART‐naive participants (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>).<br/> <sup>6</sup>No serious risk of bias: the included trial was at low risk of selection and performance bias (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>). The trial authors performed multiple imputation of viral load data. The trial authors did not provide details.<br/> <sup>7</sup>Downgraded by 2 for serious indirectness: only a single trial is available from Botswana in participants not on ART (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>).<br/> <sup>8</sup>No serious heterogeneity: all three trials reported either an increase in the mean blood selenium concentration of participants or the proportion of participants with selenium concentrations above a certain threshold level.<br/> <sup>9</sup>Downgraded by 1 for indirectness: participants in two of the three included trials were not deficient in selenium at baseline (<a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>; <a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>). The third trial reported data on participants who were selenium deficient at baseline; however it was a small subsample of the main trial from Botswana (Sales 2010). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Selenium compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Optimal information size calculations (dichotomous outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Power</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Two‐sided significance level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk in intervention group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size (total)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2412</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3%<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4782</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5%<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7314</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 cell count ≤ 350 cells/mm<sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2312</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 cell count ≤ 350 cells/mm<sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 cell count ≤ 350 cells/mm<sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Estimated annual risk of death of antiretroviral naive HIV‐infected persons (≥10 years after seroconversion) (<a href="./references#CD003650-bbs2-0095" title="Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV‐1 seroconversion to AIDS and death before widespread use of highly‐active antiretroviral therapy: a collaborative re‐analysis. Lancet2000;355(9210):1131‐7. ">Collaborative Group on AIDS Incubation 2000</a>).<br/> <sup>2</sup>Estimated annual risk of death of antiretroviral naive HIV‐infected persons (5 to 9 years after seroconversion) (<a href="./references#CD003650-bbs2-0095" title="Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV‐1 seroconversion to AIDS and death before widespread use of highly‐active antiretroviral therapy: a collaborative re‐analysis. Lancet2000;355(9210):1131‐7. ">Collaborative Group on AIDS Incubation 2000</a>).<br/> <sup>3</sup>Estimated risk of death of HIV‐infected persons after receiving first‐line antiretroviral therapy regimens for 12 months (<a href="./references#CD003650-bbs2-0108" title="MbuagbawLCE , IrlamJH , SpauldingA , RutherfordGW , SiegfriedN . Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD004246.pub3] ">Mbuagbaw 2010</a>).<br/> <sup>4</sup>Antiretroviral naive HIV‐infected participants who experience a decline in CD4 count (Kamwesiga 2011a, which is under <a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Optimal information size calculations (dichotomous outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Optimal information size calculations (continuous outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Power</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Two‐sided significance level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ratio of group 1: group 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean in supplement group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size (total)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean blood 25(OH) vitamin D level at 12 months<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean blood 25(OH) vitamin D level at 12 months<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BMI at 24 months<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BMI at 24 months <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: BMI: body mass index; SD: standard deviation.</p> <p><sup>1</sup>This example is based on data from <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>. This example uses the SD from the control group.<br/> <sup>2</sup>This example is based on data from <a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>. This example uses the SD from the supplemented group.<br/> <sup>3</sup>This example uses the SD from <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>, but uses a 1 kg/m<sup>2</sup> mean difference for illustrative purposes.<br/> <sup>4</sup>This example uses the SD from <a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a>, but uses a 2 kg/m<sup>2</sup> mean difference for illustrative purposes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Optimal information size calculations (continuous outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of trials evaluating multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline HAART use (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load</b> </p> <p><b>(copies/ml or log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMN dose<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botswana</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,800 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uganda</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.8<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (median)</p> <p>137 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus chronic diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 years<sup>4</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kenya</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (209)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (69)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363 (275)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.02 (0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malawi</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 (median)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months<sup>5</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (227)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: HAART: highly active antiretroviral therapy; MMN: multiple micronutrient; TB: Tuberculosis </p> <p><sup>1</sup>Standard dose supplements provided most of the micronutrients at the level of the Dietary Recommended Intake (DRI). High‐dose supplements provided most of the micronutrients in multiples of the DRI.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>: participants who received ART for no longer than 6 months. The rest of the trial participants were initiated on ART at baseline.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>: we excluded participants taking HAART from the analysis of CD4 and viral load.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> was a cross‐over trial, with cross‐over at the end of 1.9 years. We did not include the outcome data for the period after cross‐over.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>: the median duration of follow‐up was 12.5 months, due to the introduction of ART programme. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of trials evaluating multiple micronutrients versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Composition of multiple micronutrient supplements</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Micronutrient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> RDA male aged 19 to 70 years</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Standard doses<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>High doses<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Standard dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> High dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. "><b>Kelly 2008 ZMB</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. "><b>Zhao 2010 CHN</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. "><b>Semba 2007 MWI</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. "><b>Guwatudde 2015 UG</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. "><b>Baum 2013 BWA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. "><b>Kelly 1999 ZMB</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. "><b>Jiamton 2003 THA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. "><b>McClelland 2004 KEN</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. "><b>Range 2006 TZA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. "><b>Villamor 2008 TZA</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0018" title="IsanakaS , MugusiF , FawziWW . Standard‐dose vs high‐dose multivitamin supplements for HIV‐‐reply. JAMA2013;309(6):546. IsanakaS , MugusiF , HawkinsC , SpiegelmanD , OkumaJ , AboudS , et al. Effect of high‐dose vs standard‐dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA2012;308(15):1535‐44. PadayattySJ , LevineM . Standard‐dose vs high‐dose multivitamin supplements for HIV. JAMA2013;309(6):545‐6. "><b>Isanaka 2012 TZA</b> </a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 µg<br/> (3000 IU) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg (660 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2424µg (8000 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3182 µg (10500 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3027 µg (9990 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 µg (5000 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1515 µg (5000 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B‐carotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B1 (Thiamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B2 (riboflavin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B3 (niacin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B6 (pyridoxine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 to 1.7 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B9<br/> (folinic acid) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5000 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 µg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panthothenic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15 µg (200 to 600 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 µg (200 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 µg (200 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 µg (400 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 µg (800 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 µg (200 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Copper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chromium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Manganese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="14"> <div class="table-footnote"> <p>Abbreviations: IU: International units; RDA:Recommended Daily Allowance</p> <p><sup>1</sup>Standard dose supplements provided most of the micronutrients at the level of the RDA.<br/> <sup>2</sup>High‐dose supplements provided most of the micronutrients in multiples of the RDA. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Composition of multiple micronutrient supplements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0010"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (86 to 215)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137 (68 to 192)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐ 6.17 (95% CI ‐29.3 to 16.9)<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244 (52 to 544)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (66 to 358)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261 (50 to 550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 (73 to 377)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Did not differ"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not different"<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 (190)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>415 (242)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (212)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409 (192)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 years<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (209)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 (205)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (202)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265 (189)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted regression co‐efficient 23 (95% CI 3 to 43); P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0033" title="ZhaoF , FengXL , XuW , MaYM , WangZ , LIWJ . Effect of micronutrients on the immune status of human immunodeficiency virus‐positive individuals. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010;32(3):340‐2. ">Zhao 2010 CHN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>589 (85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466 (72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 (391)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (373)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 (385)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>403 (460)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (277)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339 (256)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 (240)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5 (−37 to 26); P = 0.74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 (336 to 555)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411 (327 to 545)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>7</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: IQR: Interquartile range; MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for end‐point data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a>: the trial authors reported a mean difference which is different to our calculation. The reasons for this are unclear.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>: the trial authors did not report data that we could include in a meta‐analysis.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> was a cross‐over trial, with cross‐over at the end of 1.9 years. CD4+ counts were recorded during the second year of follow‐up. The data for the period after cross‐over is not included in this table.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>: data shown are for multiple micronutrients plus zinc versus placebo. There were also no differences for micronutrients without zinc versus placebo.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> also reported outcomes at 8 months, with no significant difference between groups.<br/> <sup>7</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: data shown are for multivitamins plus selenium versus placebo. The trial authors reported reductions in the risk of CD4+ falling to &lt; 250 cells/µL for multivitamins plus selenium versus placebo (HR 0.48, 95% CI 0.26 to 0.88 ) and for multivitamins alone versus placebo (HR 0.54, 95% CI 0.3 to 0.98). Multivariate analysis showed that this effect was only apparent with supplementation of both multivitamins and selenium (HR 0.46, 95% CI 0.25 to 0.85). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): multiple micronutrients versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0011"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Change in viral load (log10 copies/mL): multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (3.3‐4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3 (3.6 to 4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.4<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0024" title="McClellandRS , BaetenJM , OverbaughJ , RichardsonBA , MandaliyaK , EmeryS , et al. Micronutrient supplementation increases genital tract shedding of HIV‐1 in women: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1657‐63. ">McClelland 2004 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.72 (1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.85 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not significant"<sup>5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.74 (1.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −0.08 (−0.22 to 0.05); P = 0.23</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: CI: Confidence interval; IQR: Interquartile range; MD: Mean difference; SD: Standard deviation </p> <p><sup>1</sup>The number of participants stated is the number assessed for end‐point data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: multiple imputation of viral load data was performed. The trial authors did not provide details.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: data shown are for multivitamins plus selenium versus placebo. There were also no differences for multivitamins without selenium versus placebo.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>: viral load analyses was conducted on the first 140 consecutive participants (29% of participants).<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>: data shown are for multiple micronutrients plus zinc versus placebo. There were also no differences for micronutrients without zinc versus placebo.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> also reported outcomes at 8 months, with no significant difference between groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Change in viral load (log10 copies/mL): multiple micronutrients versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0012"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Change in nutritional status parameters: multiple micronutrients versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint<br/> (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.3 (2.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.2</p> <p>(3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.1</p> <p>(−0.4 to 0.2); P = 0.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0015" title="GuwatuddeD , EzeamamaAE , BagendaD , KyeyuneR , Wabwire‐MangenF , WamaniH , et al. Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infectious Diseases2012;12:304. GuwatuddeD , WangM , ExeamamaAE , BagendaD , KyeyuneR , WamaniH , et al. The effect of standard dose multivitamin supplementation on disease progression in HIV‐infected adults initiating HAART; a randomized double blind placebo‐controlled trial in Uganda. BMC Infectious Diseases2015;15:348. ">Guwatudde 2015 UG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight (kg)</p> <p>Haemoglobin (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>12.2 (11.2 to 13.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>12.3 (11.3 to 13.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.54 (−0.40 to 1.48); P = 0.691</p> <p>MD 0.16 (−0.21 to 0.16);</p> <p>P = 0.977</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003</a><sup>12</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin E (µmol/L)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.7 (7.0 to 14.3)<sup>4</sup>; P &lt; 0.001 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µmol/L)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.16 (0.0 to 0.34)<sup>6</sup>; P = 0.04 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a><sup>12</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin A (µmol/L)<sup>7,8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin E (µmol/L)<sup>3,8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No difference"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> <p>MUAC (cm)</p> <p>Fat mass (kg)</p> <p>Lean body mass (kg)</p> <p>Grip strength (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 years <sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant differences at any time point"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a><sup>12</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood vitamin A (µmol/L)<sup>7,11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geometric mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Significantly higher"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µmol/L)<sup>10,11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geometric mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>Abbreviations: BMI: Body Mass Index; IQR: Interquartile range; MUAC: Mid‐upper arm circumference; MD: Mean difference; SD: Standard deviation </p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0031" title="VillamorE , MugusiF , UrassaW , BoschRJ , SaathoffE , MatsumotoK , et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Journal of Infectious Diseases2008;197(11):1499‐505. ">Villamor 2008 TZA</a> also reported outcomes at 8 months, with no significant difference between groups (MD 0, 95% CI −0.2 to 0.3; P = 0.74).<br/> <sup>3</sup>Reference value for vitamin E sufficiency ≥ 11.6 µmol/L.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>: the trial authors reported endpoint data on a subset of 44 participants. The trial authors did not state the number of participants for each treatment group. Baseline vitamin E levels (µmol/L) reported for 112 participants.<br/> <sup>5</sup>Reference value for selenium sufficiency: ≥ 0.95 µmol/L.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>: the trial authors reported endpoint data on a subset of 54 participants. The number of participants for each treatment group is not stated. Baseline selenium levels (µmol/L) reported for 129 participants.<br/> <sup>7</sup>Reference value for vitamin A deficiency: &lt; 0.7 µmol/L.<br/> <sup>8</sup><a href="./references#CD003650-bbs2-0021" title="KellyP , MusondaR , KafwembeE , KaetanoL , KeaneE , FarthingM . Micronutrient supplementation in the AIDS diarrhoea‐wasting syndrome in Zambia: a randomized controlled trial. AIDS1999;13(4):495‐500. ">Kelly 1999 ZMB</a>: the trial authors reported that 67% and 55% of participants were deficient in vitamins A and E, respectively, at baseline.<br/> <sup>9</sup><a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a> was a cross‐over trial, with cross‐over at the end of 1.9 years.<br/> <sup>10</sup>Reference value for selenium sufficiency: ≥ 0.75 µmol/L.<br/> <sup>11</sup><a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>: the trial authors reported that 60% and 75% of participants were deficient in vitamin A and selenium respectively, at baseline.<br/> <sup>12</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Change in nutritional status parameters: multiple micronutrients versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0013"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection not currently taking ART<br/> <b>Settings:</b> all settings<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard or high dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (14 to 52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.31 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1068<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may reduce mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> <p>(35 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p>(0.42 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>481</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on hospital admissions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 6 weeks to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>265 to 409 cells/mm</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient group was</p> <p><b>30.36 cells/mm</b> ³ <b>higher</b> </p> <p>(7.13 lower to 67.84 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,6,7</sup> </p> <p>due to indirectness and inconsistency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on CD4+ cell count</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> <p>Follow‐up: 6 to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>4.4 to 5.3 log<sub>10</sub>copies/mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.10 log<sub>10</sub>copies/mL lower</b> </p> <p>(0.27 lower to 0.07 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497</p> <p>(2 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients probably have little or no effect on viral load</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI</b> (kg/m²) </p> <p>Follow‐up: 1.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,9,10</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on BMI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; BMI: body mass index; CI: confidence interval; MUAC: mid‐upper arm circumference; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: all trials were at low risk of selection bias. Appropriate methods of blinding were used.<br/> <sup>2</sup>No serious heterogeneity: none of the trials found statistically significant effects.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: the three trials were conducted in Botswana (<a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>), Zambia (<a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>) and Thailand (<a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>).The finding of no effect may not apply to all populations.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important effects and no effect. The overall meta‐analysis is substantially underpowered to confidently exclude effects.<br/> <sup>5</sup>Downgraded by 2 for very serious indirectness: only a single trial is available from Thailand (<a href="./references#CD003650-bbs2-0019" title="JiamtonS , PepinJ , SuttentR , FilteauS , MahakkanukrauhB , HanshaoworakulW , et al. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV‐infected individuals living in Bangkok. AIDS2003;17(17):2461‐9. ">Jiamton 2003 THA</a>). The finding of no effect is not easily generalized to other settings.<br/> <sup>6</sup>Downgraded by 1 for serious inconsistency: One trial in Botswana among ART‐naive adults (not included in the meta‐analysis) reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation. This finding is inconsistent with other trials that used similar combinations of micronutrients and selenium.<br/> <sup>7</sup>Downgraded by 1 for serious indirectness: these two trials both used high‐dose multiple micronutrients and were conducted in Kenya (with 6 weeks follow‐up) and Zambia (with 1.9 years follow‐up). TThe finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>8</sup>Downgraded by 1 for serious indirectness: these two studies both used high dose multiple micronutrients and were conducted in Kenya (with 6 weeks follow‐up) and Thailand (with 48 weeks follow‐up). The finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>9</sup>Downgraded by 2 for very serious indirectness: only a single trial from Zambia (<a href="./references#CD003650-bbs2-0022" title="KellyP , KatubulushiM , ToddJ , BandaR , YambayambaV , FwoloshiM , et al. Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. American Journal of Clinical Nutrition2008;88(4):1010‐7. KellyP , ShawaT , MwanamakondoS , SokoR , SmithG , BarclayGR , et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterology2010;10:72. KellyP , ShawaT , SandersonI . Gastric hypochlorhydria and intestinal barrier dysfunction in HIV infection is not dependent on nutrition: a randomised controlled trial of supplementation. Gut2009;58:A82‐3. ">Kelly 2008 ZMB</a>) reports measures of nutritional status. This does not exclude the possibility of effects in some populations.<br/> <sup>10</sup>Downgraded by 1 for serious imprecision: this trial is underpowered to detect or exclude clinically important differences. The trial reported no difference in BMI, mid‐upper arm circumference (MUAC), lean body mass or fat mass but did not present data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0014"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection currently taking ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (20 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1,25</b> </p> <p>(0.50 to 3.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>195 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (115 to 265) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> </p> <p>(0.59 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on mortality</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was <b>147 cells/mm</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the multiple micronutrient group was <b>6.17 cells/mm</b> ³<b>lower</b> </p> <p>(29.3 lower to 16.9 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>_</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on CD4 cell count</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight</b> (kg) </p> <p>Follow‐up: 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was <b>3.3 kg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the multiple micronutrient group was <b>0.54 kg higher</b> </p> <p>(0.40 lower to 1.48 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on weight</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; HR: hazard ratio; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: this trial was at low risk of selection bias. The trial authors used appropriate methods of blinding.<br/> <sup>2</sup>Downgraded by 2 for serious indirectness: this single trial was conducted in Uganda and administered standard dose multiple micronutrients for two years. The finding of no effect may not be applicable to higher dose or the populations or settings.<br/> <sup>3</sup>Downgraded by 2 for serious imprecision: this single trial is significantly underpowered to confidently detect or exclude effects.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes what may be clinically important effects and no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0015"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis not currently taking ART</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> adults with HIV infection and concurrent active tuberculosis not currently taking ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> multiple micronutrient supplementation (standard or high dose daily)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Micronutrients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 8 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> <br/> (246 to 439) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.69 to 1.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2.3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have little or no effect on mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical disease progression from stage 3 to stage 4</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.08</b> (0.72 to 1.62 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on clinical disease progression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4 cell count</b> </p> <p>Follow‐up: 2 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>340 to 403 cells/mm</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient group was</p> <p><b>5.77 cells/mm</b> ³ <b>lower</b> </p> <p>(55.8 lower to 44.25 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>674<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have no effect on CD4 cell count</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load</b> </p> <p>Follow‐up: 2 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the placebo groups ranged from</p> <p><b>4.1 to 4.7 log<sub>10</sub>copies/mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean in the multiple micronutrient groups was</p> <p><b>0.09 log<sub>10</sub>copies/mL lower</b> </p> <p>(0.45 lower to 0.26 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343</p> <p>(2 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3,4</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple micronutrients may have no effect on viral load</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BMI in the placebo group was <b>21.2 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BMI in the micronutrient group was</p> <p><b>0.1 lower</b> </p> <p>(0.4 lower to 0.2 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,4,5</sup> </p> <p>due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if multiple micronutrients have any effect on BMI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> ART: antiretroviral therapy; CI: confidence interval; HR: hazard ratio; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: the trials were at low risk of selection bias, except for two trials that recruited both HIV‐positive and HIV‐negative participants and did not stratify the randomization (<a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>; <a href="./references#CD003650-bbs2-0028" title="SembaRD , KumwendaJ , ZijlstraE , RicksMO , vanLettowM , WhalenC , et al. Micronutrient supplements and mortality of HIV‐infected adults with pulmonary TB: a controlled clinical trial. International Journal of Tuberculosis and Lung Disease2007;11(8):854‐9. ">Semba 2007 MWI</a>). The trials used appropriate methods of blinding.<br/> <sup>2</sup>No serious heterogeneity: one small subgroup of a trial in Tanzania did find a statistically significant difference (<a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a>), but larger trials did not.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: the three trials were conducted in Tanzania and Malawi and most patients were not taking ART. The finding of no effect may not apply to people on ART or other populations and settings.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: the 95% CI is wide and includes clinically important effects and no effect.<br/> <sup>5</sup>Downgraded by 2 for serious indirectness: data is provided by a single trial from Tanzania and participants were not on antiretroviral therapy (ART). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0016"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Characteristics of trials evaluating vitamin A supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood vitamin A concentration (µmol/L)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.097 (median)</p> <p>0.095 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 (median)</p> <p>203 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.34 (median)</p> <p>5.54 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,000 IU retinol daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.42)</p> <p>1.41 (0.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300,000 IU retinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0029" title="SembaRD , RickettsEP , MehtaS , NetskiD , ThomasD , KirkG , et al. Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes2007;45(3):298‐303. ">Semba 2007 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive IDUs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61</p> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296 (median)</p> <p>259 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.49 (median)</p> <p>9.67 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200,000 IU retinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 mg β‐carotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: IDUs: Injection drug users; IU: International units; RDA: Recommended Daily Allowance </p> <p><sup>1</sup>Reference value for vitamin A sufficiency: &gt; 1.05 µmol/L.<br/> <sup>2</sup>RDA for a male aged 19 to 70 years is 900 µg (3000 IU) daily.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0009" title="CoodleyGO , NelsonHD , LovelessMO , FolkC . Beta‐carotene in HIV infection. Journal of Acquired Immune Deficiency Syndromes1993;6(3):272‐6. ">Coodley 1993 USA</a> was a cross‐over trial, with cross‐over at the end of 4 weeks. The baseline and outcome data is not reported for the period before cross‐over and therefore we could not include it. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Characteristics of trials evaluating vitamin A supplements versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0017"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): vitamin A versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of end‐point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at end‐point (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.04</p> <p>Adjusted regression coefficient 0.34 −0.22 to 0.90); P = 0.90</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>: the trial authors reported that 110 particpants completed the trial, but did not report the number of participants for each treatment group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): vitamin A versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0018"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Change in viral load (log10 copies/mL) : Vitamin A versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.1</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a>: the trial authors reported that 110 particpants completed the trial, but do not report the number of participants for each treatment group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Change in viral load (log10 copies/mL) : Vitamin A versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0019"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Change in nutritional status parameters: vitamin A versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical Measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A (µmol/L)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.03. "No effect" reported for those who were severely deficient at baseline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0027" title="SembaRD , LylesCM , MargolickJB , CaiaffaWT , FarzadeganH , CohnS , et al. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Journal of Infectious Diseases1998;177(3):611‐6. ">Semba 1998 USA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A (µmol/L)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presented in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presented in a graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not different"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0016" title="HumphreyJH , QuinnT , FineD , LedermanH , Yamini‐RoodsariS , WuLS , et al. Short‐term effects of large‐dose vitamin A supplementation on viral load and immune response in HIV‐infected women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(1):44‐51. ">Humphrey 1999 USA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin A (µmol/L)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No change"</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0003" title="BaetenJM , McClellandRS , OverbaughJ , RichardsonBA , EmeryS , LavreysL , et al. Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Journal of Infectious Diseases2002;185(8):1187‐91. ">Baeten 2002 KEN</a>: Data converted from µg/dL to µmol/L.<br/> <sup>3</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Change in nutritional status parameters: vitamin A versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0020"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Characteristics of trials evaluating Vitamin D supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood 25(OH)<sub>2</sub> vitamin D concentration (ng/mL)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2 (11.5)</p> <p>29.2 (12.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (268)</p> <p>463 (197)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,000 IU then 1200 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose at baseline then daily for 16 weeks (plus 1200 mg calcium daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive; ≤ 30 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (median)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>663 (median)</p> <p>673 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose at baseline and at 3, 6, and 9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive men and women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 (median)</p> <p>25.1 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>346 (median)</p> <p>337 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily for 48 weeks (plus 100 mg calcium)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive; ≤ 25 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 (8.4)</p> <p>17.7 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.17 (0.96)<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily for 12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guinea‐Bissau</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for HIV‐positive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for HIV‐positive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose at baseline, 5, 8 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; IU: International units; TB: Tuberculosis</p> <p><sup>1</sup>Reference value for vitamin D sufficiency: 25 (OH) vitamin D ≥ 30 ng/mL.<br/> <sup>2</sup>RDA for a male aged 19 to 70 years ranges between 5 to 15 µg (200 to 600 IU) daily.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>: only participants with low blood vitamin D concentrations were included in the trial (25(OH)D &lt; 30 ng/mL).<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>: all trial participants were intiated on ART at baseline.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>: 62% of partcipants had a CD4 cell count &gt; 500 cells/mm<sup>3</sup>.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a>: 44% of trial participants presented with a detectable viral load at baseline (vitamin D group:13, placebo group: 11). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Characteristics of trials evaluating Vitamin D supplements versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0021"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): vitamin D versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (268)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 (197)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No changes" in naïve or activated CD4+ cell counts</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 58.1 (−114.5 to 230.7)<sup>2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>346</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>551<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>526<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −22 (P = 0.17)<sup>4</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a>: the trial authors also reported no difference in CD4+ cell count at 3, 6, and 9 months.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a>: the trial authors reported an increase in CD4+ cell count within both treatment groups (P &gt; 0.001).<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0032" title="WejseC , GomesVF , RabnaP , GustafsonP , AabyP , LisseIM , et al. Vitamin D as supplementary treatment for tuberculosis: a double‐blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2009;179(9):843‐50. ">Wejse 2009 GNB</a>: subset of 41 HIV‐positive participants who had CD4+ cell counts at baseline and endpoint. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): vitamin D versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0022"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Change in nutritional status parameters: vitamin D versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical Measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint<br/> (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0004" title="BangU , KolteL , HitzM , Dam NielsenS , SchierbeckLL , AndersenO , et al. Correlation of increases in 1,25‐dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV‐1‐infected males. HIV Clinical Trials2012;13(3):162‐70. BangUC , KolteL , HitzM , SchierbeckLL , NielsenSD , BenfieldT , et al. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1‐infected males: results of a clinical trial. AIDS Research and Human Retroviruses2013;29(4):658‐64. ">Bang 2012 DEN</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2 (11.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.6 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (12.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2 (13.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0012" title="GiacometV , ViganoA , ManfrediniV , CeriniC , BedogniG , MoraS , et al. Cholecalciferol supplementation in HIV‐infected youth with vitamin D insufficiency: effects on vitamin D status and T‐cell phenotype: a randomized controlled trial. HIV Clinical Trials2013;14(2):51‐60. ">Giacomet 2013 ITA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 12.5 (5.9 to 19) P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0025" title="OvertonET , ChanES , BrownTT , TebasP , McComseyGA , MelbourneKM , et al. High‐dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Annals of Internal Medicine2015;162(12):815‐24. [DOI: 10.7326/M14‐1409] ">Overton 2015 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0030" title="StallingsVA , SchallJI , HedigerML , ZemelBS , TulucF , DoughertyKA , et al. High‐dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo‐controlled trial. Paediatric Infectious Disease Journal2014;34(2):e32‐40. ">Stallings 2014 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25(OH) vitamin D (ng/mL)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.3 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (13.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 (6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>Abbreviations: MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for end‐point data.<br/> <sup>2</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Change in nutritional status parameters: vitamin D versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0023"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Characteristics of trials evaluating zinc supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood zinc concentration (µg/L)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (copies/mL or log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% with immunological discordance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (median)</p> <p>76 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (median)</p> <p>162 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62%<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (10)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373 (280)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg (women)</p> <p>15 mg (men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peru</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus persistent diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (median)</p> <p>65 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (median)</p> <p>55 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singapore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.9 (15.0)</p> <p>92.2 (18.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (62)</p> <p>131 (65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 338 (38 335)</p> <p>28 093 (41 056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nigeria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mg weekly<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive plus active TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406 (median)</p> <p>460 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83 (median)</p> <p>3.90 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: ART: Antiretroviral therapy; RDA: Recommended Daily Allowance; TB: Tuberculosis </p> <p><sup>1</sup>Reference value for zinc sufficiency: &gt; 70 µg/L.<br/> <sup>2</sup>RDA for a male aged 18 to 70 years is 11 mg daily.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>: the trial authors stratified participants with or without low blood zinc concentrations and randomized them to receive zinc or placebo.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>: proportion of trial participants who were on ART and had an undetectable viral load at baseline: 30%<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>: the trial authors excluded participants with normal baseline blood zinc levels (≥ 75 µg/L)<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0023" title="LawsonL , ThacherTD , YassinMA , OnuohaNA , UsmanA , EmenyonuNE , et al. Randomized controlled trial of zinc and vitamin A as co‐adjuvants for the treatment of pulmonary tuberculosis. Tropical Medicine &amp; International Health2010;15(12):1481‐90. ">Lawson 2010 NIG</a>: the trial authors randomized participants to receive either weekly doses of zinc (90 mg) and vitamin A (5000 IU), zinc (90 mg) and placebo, or a dual placebo. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Characteristics of trials evaluating zinc supplements versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0024"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Change in CD4 count (cells/mm3) : zinc versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>(IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> <p>(151 to 213)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> <p>(190 to 286)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> <p>(139 to 182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> <p>(162 to 254)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>17</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supplementation increased median CD4+ in those with low zinc at baseline (P = 0.042) but not those with normal zinc (P &gt; 0.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385</p> <p>(285)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361</p> <p>(275)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduced risk of CD4+ &lt; 200 cells/µL<sup>2</sup> with intervention (RR 0.24, 95% CI 0.10 to 0.56) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> <p>(61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> <p>(73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> <p>(63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> <p>(75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> <p>(327 to 485)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>422</p> <p>(331 to 512)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460<br/> (351 to 569) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>403</p> <p>(309 to 569)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not significant"</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: CI: Confidence interval; IQR: Interquartile range; RR: Relative risk; SD: Standard deviation </p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Change in CD4 count (cells/mm3) : zinc versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0025"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Change in viral load (copies/mL or log10 copies/mL): zinc versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> <p>(1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> <p>(1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not affected by supplementation"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,740</p> <p>(36,856)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,652</p> <p>(39,418)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,286</p> <p>(40,297)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,551</p> <p>(39,013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0026" title="RangeN , ChangaluchaJ , KrarupH , MagnussenP , AndersenAB , FriisH . The effect of multi‐vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two‐by‐two factorial trial in Mwanza, Tanzania. British Journal of Nutrition2006;95(4):762‐70. ">Range 2006 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<br/> (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83 (3.52 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.28 (3.86 to 4.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (3.53 to 4.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (3.67 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Not significant"</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: CI: Confidence interval; SD: Standard deviation; TB: Tuberculosis</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Change in viral load (copies/mL or log10 copies/mL): zinc versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0026"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Changes in nutritional status parameters: zinc versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical Measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint (as reported by trial authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>(IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> <p>(66 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> <p>(71 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(66 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(69 to 82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"higher after zinc supplementation, particularly in patients with low plasma zinc levels at baseline" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>(SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted<sup>4</sup> regression coefficient ß = 0.04; P = 0.0472 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0013" title="GreenJA , LewinSR , WightmanF , LeeM , RavindranS , PatonNI . A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV‐infected patients. International Journal of Tuberculosis and Lung Disease2005;9(12):1378‐84. ">Green 2005 SGP</a><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood zinc (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.2 (18.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120.3 (68.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.9 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111.8 (37.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.67</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>Abbreviations: IQR: Interquartile range; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0002" title="AsdamongkolN , PhanachetP , SungkanoparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Journal of the International AIDS Society2012;15(Suppl 4):152‐3. AsdamongkolN , PhanachetP , SungkanuparphS . Low plasma zinc levels and immunological responses to zinc supplementation in HIV‐infected patients with immunological discordance after antiretroviral therapy. Japanese Journal of Infectious Diseases2013;66(6):469‐74. ">Asdamongkol 2013 THA</a>: participants with or without low blood zinc concentrations were stratified and randomized to receive zinc or placebo.<br/> <sup>3</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0005" title="BaumMK , LaiS , SalesS , PageJB , CampaA . Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV‐infected adults. Clinical Infectious Diseases2010;50(12):1653‐60. [PUBMED: 20455705] LimaC , CampaA , SalesS , StewartT , GarcesL , BaumMK . Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami. FASEB Journal2010;24(1 Supplement):718.7. ">Baum 2010 USA</a>: regression coefficient adjusted for C‐reactive protein levels (biomarker for inflammation).<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0008" title="CárcamoC , HootonT , WeissNS , GilmanR , WenerMH , ChavezV , et al. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. Journal of Acquired Immune Deficiency Syndromes2006;43(2):197‐201. ">Cárcamo 2006 PER</a>: the trial authors reported a smaller proportion of participants in the supplemented group with low zinc levels after 14 days of follow‐up (65.6% versus 93.7%; P = 0.01). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Changes in nutritional status parameters: zinc versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0027"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Characteristics of trials evaluating selenium supplements versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline ART use</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline blood selenium concentration (µg/l)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline CD4+ cell count (cells/mm<sup>3</sup>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean baseline viral load (copies/mL or log<sub>10</sub> copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of supplementation (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botswana</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (10)</p> <p>70 (24)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 500 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive IDUs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy 21%</p> <p>HAART 46%<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427 (421)</p> <p>378 (295)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55,257 (147, 152)</p> <p>60,905 (144, 292)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (264)</p> <p>441 (266)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,558 (87,051)</p> <p>10,491 (20,251)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rwanda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552 (median)</p> <p>527 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (median)</p> <p>3.9 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; HAART: Highly active antiretroviral therapy; IDUs: injection drug users. </p> <p><sup>1</sup>Reference values used to define selenium sufficiency: &gt; 75 µg/L or &gt; 85 µg/L<br/> <sup>2</sup>RDA for a male aged 18 to 70 years is 55 µg daily.<br/> <sup>3</sup>Sales 2010 BWA in <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: Baseline selenium concentrations reported for a sub‐sample of 79 trial participants.<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: the trial authors reported fewer ARV naive participants in the selenium group (24%) compared to the placebo group (37%) at baseline.<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: participants with low baseline blood selenium levels (≤ 85 µg/L) were excluded from the trial.<br/> <sup>6</sup><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>: participants with low baseline blood selenium levels (≤ 75 µg/L) were excluded from the trial.<br/> <sup>7</sup><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>: participants who were eligible for ART were excluded from the trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Characteristics of trials evaluating selenium supplements versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0028"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): selenium versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Difference between groups<br/> at endpoint<br/> (as reported by study authors)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>(IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423</p> <p>(347 to 539)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411</p> <p>(327 to 545)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427(421)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376(295)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (264)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441 (266)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552 (470 to 636)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527 (465 to 610)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<sup>5</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; HR: hazard ratio; IQR: interquartile range; RR: risk ratio; SD: standard deviation<br/> <sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup><a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>: the trial authors reported no reduction in risk of CD4+ falling to &lt; 250 cells/µL<sup>2</sup> (HR 0.83, 95% CI 0.48 to 1.42).<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: the trial authors reported that 46% of participants in the placebo group versus 25% in the selenium group experienced a decline in CD4 cell count &gt; 50 cells/mm<sup>3</sup> (P = 0.01).<br/> <sup>4</sup><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a>: the trial authors reported in a multiple regression model that increased selenium levels predicted a greater decrease in viral load (P &lt; 0.02), which predicted a greater increase in CD4 counts (P &lt; 0.04).<br/> <sup>5</sup><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a>: the trial authors reported a 44 % reduction in the rate of CD4+ cell decline per month (MD 1.74, 95% CI 0.31 to 3.17). No reduction in risk of CD4+ falling to &lt; 350 cells/µL<sup>2</sup> (RR 0.81, 95% CI 0.61 to 1.09). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Change in CD4 cell count (cells/mm3): selenium versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003650-tbl-0029"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Change in nutritional status parameters: selenium versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nutritional parameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Statistical measure</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Timing of endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported <sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0017" title="HurwitzBE , KlausJR , LlabreMM , GonzalezA , LawrencePJ , MaherKJ , et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine2007;167(2):148‐54. ">Hurwitz 2007 USA</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 31.7 (27.4 to 36); P&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003650-bbs2-0020" title="KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , SmythR , FayH , et al. Effect of selenium supplementation on CD4 T‐cell count recovery, viral suppression, morbidity and quality of life of HIV‐infected patients in Rwanda: study protocol for randomized controlled trial. Trials2011;12:192. KamwesigaJ , MutabaziV , KayumbaJ , TayariJK , UwimbabaziJC , BatanageG , et al. Effect of selenium supplementation on CD4+ T‐cell recovery, viral suppression and morbidity of HIV‐infected patients in Rwanda: a randomized controlled trial. AIDS2015;29(9):1045‐52. ">Kamwesiga 2015 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sales 2010<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood selenium (µg/L)<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 (15.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (12.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P&lt;0.001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>Abbreviations: MD: Mean difference; SD: Standard deviation</p> <p><sup>1</sup>The number of participants stated is the number assessed for endpoint data.<br/> <sup>2</sup>Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.<br/> <sup>3</sup><a href="./references#CD003650-bbs2-0007" title="BurbanoX , Miguez‐BurbanoMJ , McCollisterK , ZhangG , RodriguezA , RuizP , et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV‐infected participants. HIV Clinical Trials2002;3(6):483‐91. ">Burbano 2002 USA</a>: the trial authors reported proportions of participants with blood selenium levels &lt; 135 µg/L at the end of the trial: 89% versus 47% (P = 0.001).<br/> <sup>4</sup>Sales 2010: data reported on a subsample of trial participants from the trial by <a href="./references#CD003650-bbs2-0006" title="BaumMK , CampaA , LaiS , Sales MartinezS , TsalaileL , BurnsP , et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral‐naive, HIV‐infected adults in Botswana: a randomized clinical trial. JAMA2013;310(20):2154‐63. [DOI: 10.1001/jama.2013.280923] SalesS , TsalaileL , BurnsPJ , CampaA , MakhemaJ , MarlinkR , et al. Selenium (Se) supplementation for 6 months increases plasma selenium levels in HIV+ adults in Botswana. FASEB Journal2010;24(1 Supplement):916.10. ">Baum 2013 BWA</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Change in nutritional status parameters: selenium versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/full#CD003650-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003650-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Multiple micronutrients versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.72, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 People with HIV not on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.31, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 People with HIV on ART or initiating ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.50, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 People with HIV not on ART and on treatment for active tuberculosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.69, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.61, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 People with HIV not on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.42, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 People with HIV on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical disease progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 People with HIV not on ART and on treatment for active tuberculosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 CD4+ cell count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.27 [‐55.97, 19.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 At longest follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.40 [‐22.91, 75.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 CD4+ cell count at longest follow‐up; subgrouped by participant characteristics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 People with HIV not on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.36 [‐7.13, 67.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 People with HIV on ART or initiating ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐35.87, 23.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 People with HIV not on ART and on treatment for active tuberculosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.77 [‐55.80, 44.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 People with HIV ‐ Not stated if they are taking ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>106.0 [77.23, 134.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Viral load <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.16, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 At longest follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.26, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Viral load at longest follow‐up; sub‐grouped by participant characteristics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 People with HIV not on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.27, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 People with HIV not on ART but in treatment for active tuberculosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.45, 0.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Multiple micronutrients versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003650-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High dose multivitamins versus standard dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.89, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 People with HIV on ART or initiating ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.89, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 CD4+ cell count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.20 [‐14.08, ‐2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.0 [‐13.74, ‐0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.0 [‐22.00, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Viral load <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.51, 0.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High dose multivitamins versus standard dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003650-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin D versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 People with HIV not on ART and on treatment for active tuberculosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.65, 2.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin D versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003650-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zinc versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.53, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 People with HIV on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.58, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 People with HIV not on ART and on treatment for active tuberculosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.22, 11.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persistence of diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 People with HIV not on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rate of diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.18, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 People with HIV on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.18, 0.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zinc versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003650-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Selenium versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.21, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 People with HIV on ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.21, 0.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Selenium versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003650.pub4/references#CD003650-tbl-0034">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003650.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003650-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003650-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003650-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003650-note-0002">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003650-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003650-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003650-note-0040">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003650\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003650\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003650\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003650\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003650\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003650.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003650.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003650.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003650.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003650.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717565255"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003650.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717565258"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003650.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbb07688d9371',t:'MTc0MDcxNzU2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 